#Coronavirus Disease Research #References (by AMEDEO, May 11 ’24)

1. MONZON R, Ornelas-Dorian C, Eucker SA, Rising K, et al
   An evaluation of COVID-19 vaccine messaging platforms in the emergency department.
   Acad Emerg Med. 2024 May 5. doi: 10.1111/acem.14933.
   PubMed        
   
   
   Antiviral Res
2. SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al
   Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond.
   Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903.
   PubMed         Abstract available
   
   
   BMJ
3. 
   Seven days in medicine: 1-7 May 2024.
   BMJ. 2024;385:q1022.
   PubMed        
   
4. MAHASE E
   Workforce and winter under Labour: Wes Streeting on his plan for the NHS and ending the strikes.
   BMJ. 2024;385:q992.
   PubMed        
   
5. WONG G, Kelly M
   NHS funding for a secure future: naming the elephant in the room.
   BMJ. 2024;385:q1036.
   PubMed        
   
6. NAKWEYA G
   Moderna’s decision to shelve vaccine plant in Kenya should encourage global south’s self-reliance, says global health adviser.
   BMJ. 2024;385:q1051.
   PubMed        
   
7. MAFI A
   Doctors in training should be at the top of the workforce priority list.
   BMJ. 2024;385:q1045.
   PubMed        
   
8. WATERS A
   LMC removes GP from committee amid row over attendance at meetings.
   BMJ. 2024;385:q1021.
   PubMed        
   
9. LOOI MK
   Why WHO changed the definition of “airborne transmission” in the wake of the pandemic.
   BMJ. 2024;385:q985.
   PubMed        
   
10. LYNN E
    April top picks: Hope springs eternal.
    BMJ. 2024;385:q1037.
    PubMed        
    
    
    Clin Infect Dis
11. ANDREWS JS, Boonyaratanakornkit JB, Krusinska E, Allen S, et al
    Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A Randomized Phase 2 Trial of RSLV-132.
    Clin Infect Dis. 2024 May 10:ciae205. doi: 10.1093.
    PubMed         Abstract available
    
    
    Int J Infect Dis
12. XIANG Y, Feng Y, Qiu J, Zhang R, et al
    Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: a study using data from the UK Biobank.
    Int J Infect Dis. 2024 May 1:107080. doi: 10.1016/j.ijid.2024.107080.
    PubMed         Abstract available
    
13. SCOTT AJ, Limbada M, Perumal T, Jaumdally S, et al
    Integrating molecular and radiological screening tools during community-based active case-finding for tuberculosis and COVID-19 in southern Africa.
    Int J Infect Dis. 2024 May 1:107081. doi: 10.1016/j.ijid.2024.107081.
    PubMed         Abstract available
    
14. VAN VOORDEN J, de Groot CJM, Ris-Stalpers C, Afink GB, et al
    Corrigendum to “COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development” [International Journal of Infectious Diseases, 140C (2024) pages 95-98].
    Int J Infect Dis. 2024;144:107068.
    PubMed        
    
15. LIN DY, Xu Y, Gu Y, Sunny SK, et al
    Impact of Booster Vaccination Interval on SARS-CoV-2 Infection, Hospitalization, and Death.
    Int J Infect Dis. 2024 May 3:107084. doi: 10.1016/j.ijid.2024.107084.
    PubMed         Abstract available
    
    
    Intensive Care Med
16. MONTOMOLI J, Vergano M, Semeraro F, Bignami EG, et al
    From the pandemic to a war: a call for solidarity with all healthcare workers.
    Intensive Care Med. 2024;50:776-777.
    PubMed        
    
17. DE CORTE T, Kohler K, Cecconi M, De Waele JJ, et al
    Characteristics of co-infection and secondary infection amongst critically ill COVID-19 patients in the first two waves of the pandemic.
    Intensive Care Med. 2024 May 6. doi: 10.1007/s00134-024-07444.
    PubMed        
    
    
    Invest Radiol
18. ECKSTEIN J, Skeries V, Pohler G, Babazade N, et al
    Multiparametric Cardiovascular MRI Assessment of Post-COVID Syndrome in Children in Comparison to Matched Healthy Individuals.
    Invest Radiol. 2024;59:472-478.
    PubMed         Abstract available
    
    
    J Infect
19. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    PubMed         Abstract available
    
20. HALVORSEN B, Viermyr HK, Ueland T, Sagen EL, et al
    IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement.
    J Infect. 2024 May 6:106176. doi: 10.1016/j.jinf.2024.106176.
    PubMed        
    
    
    J Med Virol
21. FENG Y, Zhao X, Chen Z, Wu Y, et al
    Prevalence and diversity of imported severe acute respiratory syndrome coronavirus 2 variants in China, 2021-2022.
    J Med Virol. 2024;96:e29664.
    PubMed         Abstract available
    
22. ISHII T, Nawa N, Hosokawa S, Morio T, et al
    Exploring viral infections’ role in Kawasaki disease onset: A study during the COVID-19 pandemic.
    J Med Virol. 2024;96:e29660.
    PubMed         Abstract available
    
23. ASHOKKUMAR S, Lim JS, Kaushik NK, Han I, et al
    Human coronavirus 229E inactivation on porous and nonporous materials using dielectric barrier discharge (DBD) plasma.
    J Med Virol. 2024;96:e29655.
    PubMed         Abstract available
    
24. WU JY, Chen CC, Liu MY, Hsu WH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    J Med Virol. 2024;96:e29662.
    PubMed         Abstract available
    
25. CHENG P, Zhai K, Han W, Zeng J, et al
    Characterizing the antigenic evolution of pandemic influenza A (H1N1) pdm09 from 2009 to 2023.
    J Med Virol. 2024;96:e29657.
    PubMed         Abstract available
    
26. CHEN SY, Hsieh TYJ, Hung YM, Oh JW, et al
    Prior COVID-19 vaccination and reduced risk of cerebrovascular diseases among COVID-19 survivors.
    J Med Virol. 2024;96:e29648.
    PubMed         Abstract available
    
27. RZYMSKI P, Zarebska-Michaluk D, Parczewski M, Genowska A, et al
    The burden of infectious diseases throughout and after the COVID-19 pandemic (2020-2023) and Russo-Ukrainian war migration.
    J Med Virol. 2024;96:e29651.
    PubMed         Abstract available
    
28. GRUBER CEM, Tucci FG, Giombini E, Mazzotta V, et al
    Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.
    J Med Virol. 2024;96:e29642.
    PubMed         Abstract available
    
    
    J Virol
29. ADAIR A, Tan LL, Feng J, Girkin J, et al
    Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.
    J Virol. 2024 May 6:e0053124. doi: 10.1128/jvi.00531.
    PubMed         Abstract available
    
30. YU M, Li J, Gao W, Li Z, et al
    Multiple E3 ligases act as antiviral factors against SARS-CoV-2 via inducing the ubiquitination and degradation of ORF9b.
    J Virol. 2024 May 6:e0162423. doi: 10.1128/jvi.01624.
    PubMed         Abstract available
    
    
    JAMA
31. HARRIS E
    National Academies Report: COVID-19 Vaccines Don’t Cause Many Potential Harms.
    JAMA. 2024 May 10. doi: 10.1001/jama.2024.7724.
    PubMed        
    
32. ANDERER S
    Could “Empathetic Refutation” Help Clinicians Sway Vaccine Skeptics?
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.4493.
    PubMed        
    
33. AGRAWAL S, Ross JS, Ramachandran R
    Implications for Public Health Regulation if Chevron Deference Is Overturned.
    JAMA. 2024;331:1443-1444.
    PubMed        
    
34. HARRIS E
    Trials Will Evaluate Treatments for Long COVID Nervous System Problems.
    JAMA. 2024;331:1439-1440.
    PubMed        
    
    
    Lancet
35. KIVIMAKI M, Batty GD
    Work as a health risk.
    Lancet. 2024;403:1747-1748.
    PubMed        
    
    
    Lancet Infect Dis
36. WANG H, Wei Y, Hung CT, Lin G, et al
    Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
    Lancet Infect Dis. 2024 May 3:S1473-3099(24)00217.
    PubMed         Abstract available
    
37. ARES-GOMEZ S, Mallah N, Santiago-Perez MI, Pardo-Seco J, et al
    Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Lancet Infect Dis. 2024 Apr 30:S1473-3099(24)00215.
    PubMed         Abstract available
    
38. SORIANO V, Moreno-Torres V
    Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection.
    Lancet Infect Dis. 2024 May 3:S1473-3099(24)00258.
    PubMed        
    
    
    Nature
39. DESAUTELS TA, Arrildt KT, Zemla AT, Lau EY, et al
    Computationally restoring the potency of a clinical antibody against Omicron.
    Nature. 2024 May 8. doi: 10.1038/s41586-024-07385.
    PubMed         Abstract available
    
    
    Science
40. THORP HH
    Mr. Thorp goes to Washington.
    Science. 2024;384:601.
    PubMed         Abstract available
    
41. COHEN J
    Virus gone wild.
    Science. 2024;384:615-617.
    PubMed         Abstract available
    
    
    Zhonghua Jie He He Hu Xi Za Zhi
42. YANG LL, Huang LT, Ren SY, Ouyang RY, et al
    [COVID-19 in patients with Good syndrome: report of 4 cases and literature review].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:430-436.
    PubMed         Abstract available
    
43. LIU MH, Sun YX, Li ZL, Zhang LJ, et al
    [Retrospective analysis of diagnosis and treatment of tuberculosis in designated medical institutions in China from 2017 to 2022].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:437-443.
    PubMed         Abstract available
    
44. GU SJ, Wen JL, Wang XY, Zhang LX, et al
    [Progress in the diagnose and treatment of pulmonary arterial thrombosis in situ].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:464-469.
    PubMed         Abstract available

#Influenza and other Respiratory Viruses Research #References (by AMEDEO, May 11 ’24)

1. LIN X, Chen X, Chen Y, Xu P, et al
   Sleep initiation patterns and sleep quality among toddlers in the southeast of China: initial study results.
   BMC Pediatr. 2024;24:298.
   PubMed         Abstract available
   
   
   BMJ
2. 
   Seven days in medicine: 1-7 May 2024.
   BMJ. 2024;385:q1022.
   PubMed        
   
3. MAHASE E
   Workforce and winter under Labour: Wes Streeting on his plan for the NHS and ending the strikes.
   BMJ. 2024;385:q992.
   PubMed        
   
4. WONG G, Kelly M
   NHS funding for a secure future: naming the elephant in the room.
   BMJ. 2024;385:q1036.
   PubMed        
   
5. NAKWEYA G
   Moderna’s decision to shelve vaccine plant in Kenya should encourage global south’s self-reliance, says global health adviser.
   BMJ. 2024;385:q1051.
   PubMed        
   
6. MAFI A
   Doctors in training should be at the top of the workforce priority list.
   BMJ. 2024;385:q1045.
   PubMed        
   
7. WATERS A
   LMC removes GP from committee amid row over attendance at meetings.
   BMJ. 2024;385:q1021.
   PubMed        
   
8. LOOI MK
   Why WHO changed the definition of “airborne transmission” in the wake of the pandemic.
   BMJ. 2024;385:q985.
   PubMed        
   
9. LYNN E
   April top picks: Hope springs eternal.
   BMJ. 2024;385:q1037.
   PubMed        
   
   
   Epidemiol Infect
10. GUERRERO-SOLER M, Gras-Valenti P, Gomez-Sotero IL, Platas-Abenza G, et al
    Impact of COVID-19 on the degree of compliance with hand hygiene: a repeated cross-sectional study.
    Epidemiol Infect. 2024;152:e69.
    PubMed         Abstract available
    
    
    J Clin Microbiol
11. SMY L, Ledeboer NA, Wood MG
    At-home testing for respiratory viruses: a minireview of the current landscape.
    J Clin Microbiol. 2024;62:e0031223.
    PubMed         Abstract available
    
    
    J Epidemiol Community Health
12. YEUNG A, Wilkinson M, Bishop J, Taylor B, et al
    SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland.
    J Epidemiol Community Health. 2024;78:380-387.
    PubMed         Abstract available
    
    
    J Gen Virol
13. KARA Y, Kizil MC, Iseri Nepesov M, Kacmaz E, et al
    Assessing the change in the epidemiology of seasonal respiratory viruses with the onset of the COVID-19 pandemic.
    J Gen Virol. 2024;105.
    PubMed         Abstract available
    
    
    J Immunol
14. BOUCHER J, Gilbert C, Bose S, Tessier PA, et al
    S100A9: The Unusual Suspect Connecting Viral Infection and Inflammation.
    J Immunol. 2024;212:1523-1529.
    PubMed         Abstract available
    
15. SAITO S, Bozorgmehr N, Sligl W, Osman M, et al
    The Role of Coinhibitory Receptors in B Cell Dysregulation in SARS-CoV-2-Infected Individuals with Severe Disease.
    J Immunol. 2024;212:1540-1552.
    PubMed         Abstract available
    
    
    J Infect Dis
16. HOY G, Stadlbauer D, Balmaseda A, Kuan G, et al
    Humoral correlates of protection against influenza A H3N2 virus infection.
    J Infect Dis. 2024 May 9:jiae258. doi: 10.1093.
    PubMed         Abstract available
    
    
    JAMA
17. AGRAWAL S, Ross JS, Ramachandran R
    Implications for Public Health Regulation if Chevron Deference Is Overturned.
    JAMA. 2024;331:1443-1444.
    PubMed        
    
18. HARRIS E
    Trials Will Evaluate Treatments for Long COVID Nervous System Problems.
    JAMA. 2024;331:1439-1440.
    PubMed        
    
19. HARRIS E
    Safety Concerns Put a Stop to Maternal RSV Vaccine Study.
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.5155.
    PubMed        
    
20. HARRIS E
    COVID-19 Vaccination Linked With Lower Risk of Cardiac Problems.
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.5152.
    PubMed        
    
21. ANDERER S
    Could “Empathetic Refutation” Help Clinicians Sway Vaccine Skeptics?
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.4493.
    PubMed        
    
    
    Lancet
22. KIVIMAKI M, Batty GD
    Work as a health risk.
    Lancet. 2024;403:1747-1748.
    PubMed        
    
23. ZUMLA A, Peiris M, Memish ZA, Perlman S, et al
    Anticipating a MERS-like coronavirus as a potential pandemic threat.
    Lancet. 2024 Apr 8:S0140-6736(24)00641-X. doi: 10.1016/S0140-6736(24)00641.
    PubMed        
    
    
    Pediatrics
24. MORO PL, Scheffey A, Gallego R, Jones JM, et al
    Incorrect Administration of Adult RSV Vaccines to Young Children.
    Pediatrics. 2024;153:e2024066174.
    PubMed        
    
    
    PLoS Comput Biol
25. BOUMAN JA, Hauser A, Grimm SL, Wohlfender M, et al
    Bayesian workflow for time-varying transmission in stratified compartmental infectious disease transmission models.
    PLoS Comput Biol. 2024;20:e1011575.
    PubMed         Abstract available
    
    
    PLoS One
26. SELVAVINAYAGAM TS, Viswanathan V, Ramalingam A, Kangusamy B, et al
    Prevalence of Noncommunicable Disease (NCDs) risk factors in Tamil Nadu: Tamil Nadu STEPS Survey (TN STEPS), 2020.
    PLoS One. 2024;19:e0298340.
    PubMed         Abstract available
    
27. VOLTMER K, von Salisch M
    Longitudinal prediction of primary school children’s COVID-related future anxiety in the second year of the pandemic in Germany.
    PLoS One. 2024;19:e0302065.
    PubMed         Abstract available
    
28. IQBAL NT, Ahmed K, Sattar T, Aziz F, et al
    BCG activation of trained immunity is associated with induction of cross reactive COVID-19 antibodies in a BCG vaccinated population.
    PLoS One. 2024;19:e0302722.
    PubMed         Abstract available
    
29. VAMEGHI M, Saatchi M, Bahrami G, Soleimani F, et al
    How did we protect children against COVID-19 in Iran? Prevalence of COVID-19 and vaccination in the socio-economic context of COVID-19 epidemic.
    PLoS One. 2024;19:e0303043.
    PubMed         Abstract available
    
30. MALKOWSKI OS, Townsend NP, Kelson MJ, Foster CEM, et al
    Socio-economic inequalities in the breadth of internet use before and during the COVID-19 pandemic among older adults in England.
    PLoS One. 2024;19:e0303061.
    PubMed         Abstract available
    
31. AL MAQBALI M, Alsayed A, Hughes C, Hacker E, et al
    Stress, anxiety, depression and sleep disturbance among healthcare professional during the COVID-19 pandemic: An umbrella review of 72 meta-analyses.
    PLoS One. 2024;19:e0302597.
    PubMed         Abstract available
    
32. OMALE UI, Ikegwuonu CO, Nkwo GE, Nwali UIA, et al
    COVID-19 and COVID-19 vaccination experiences and perceptions among health workers during the pandemic in Ebonyi state, Nigeria: An analytical cross-sectional study.
    PLoS One. 2024;19:e0303172.
    PubMed         Abstract available
    
33. AGGARWAL S, Singh L, Alam U, Sharma S, et al
    COVID-19 vaccine hesitancy among adults in India: A primary study based on health behavior theories and 5C psychological antecedents model.
    PLoS One. 2024;19:e0294480.
    PubMed         Abstract available
    
34. LIU X, Xie CP
    Person-organization fit and job burnout of researchers during the COVID-19 pandemic: Heterogeneity in eleven countries.
    PLoS One. 2024;19:e0302296.
    PubMed         Abstract available
    
35. NAPOLITANO JM, Srikanth S, Noorai RE, Wilson S, et al
    SARS-CoV-2 variant introduction following spring break travel and transmission mitigation strategies.
    PLoS One. 2024;19:e0301225.
    PubMed         Abstract available
    
36. MEYER C, Crayton E, Wright A, Spyer M, et al
    Factors influencing uptake of protective behaviours by healthcare workers in England during the COVID-19 pandemic: A theory-based mixed-methods study.
    PLoS One. 2024;19:e0299823.
    PubMed         Abstract available
    
37. GALIERO R, Loffredo G, Simeon V, Caturano A, et al
    Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy.
    PLoS One. 2024;19:e0296495.
    PubMed         Abstract available
    
38. PASAT Z, Sinn CJ, Rahman B, Gayowsky A, et al
    The relationship between patient experience and real-world digital health access in primary care: A population-based cross-sectional study.
    PLoS One. 2024;19:e0299005.
    PubMed         Abstract available
    
39. SCOGLIO AAJ, Nishimi K, Choi KW, Koenen KC, et al
    Prior resilience to trauma & coping during the COVID-19 pandemic.
    PLoS One. 2024;19:e0297169.
    PubMed         Abstract available
    
40. GROSS RS, Thaweethai T, Rosenzweig EB, Chan J, et al
    Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design.
    PLoS One. 2024;19:e0285635.
    PubMed         Abstract available
    
41. ROCA C, Asturizaga A, Villca N, Cabrera R, et al
    Relationship between sociodemographic, clinical, and laboratory characteristics and severity of COVID-19 in pediatric patients.
    PLoS One. 2024;19:e0283037.
    PubMed         Abstract available
    
42. FERNANDEZ D, Perez-Alvarez N, Molist G
    COVID-19 patient profiles over four waves in Barcelona metropolitan area: A clustering approach.
    PLoS One. 2024;19:e0302461.
    PubMed         Abstract available
    
43. DE WITTE D, Abad AA, Neyens T, Verbeke G, et al
    A joint penalized spline smoothing model for the number of positive and negative COVID-19 tests.
    PLoS One. 2024;19:e0303254.
    PubMed         Abstract available
    
44. AALOKKEN TM, Ashraf H, Einvik G, Lerum TV, et al
    CT abnormalities 3 and 12 months after hospitalization for COVID-19 and association with disease severity: A prospective cohort study.
    PLoS One. 2024;19:e0302896.
    PubMed         Abstract available
    
45. GNADE CM, Avery CC, Yang Z, Pickett CM, et al
    Social media trends in obstetrics and gynecology residency programs on Instagram and X (Twitter).
    PLoS One. 2024;19:e0296930.
    PubMed         Abstract available
    
46. CARDENAS-CALLE M, Patino L, Pernia B, Erazo R, et al
    Detection of thermotolerant coliforms and SARS-CoV-2 RNA in sewage and recreational waters in the Ecuadorian coast: A call for improving water quality regulation.
    PLoS One. 2024;19:e0302000.
    PubMed         Abstract available
    
47. KIM S, Lilani A, Redemptus C, Campana K, et al
    A pre-post evaluation study of a social media-based COVID-19 communication campaign to improve attitudes and behaviors toward COVID-19 vaccination in Tanzania.
    PLoS One. 2024;19:e0300206.
    PubMed         Abstract available
    
48. WEBB EJD, Conaghan PG, Henderson M, Hulme C, et al
    Long-term health conditions and UK labour market outcomes during the COVID-19 pandemic.
    PLoS One. 2024;19:e0302746.
    PubMed         Abstract available
    
49. DU W, Zhao L, Wu R, Huang B, et al
    Predicting drug-Protein interaction with deep learning framework for molecular graphs and sequences: Potential candidates against SAR-CoV-2.
    PLoS One. 2024;19:e0299696.
    PubMed         Abstract available
    
50. ELIAS TP, Gebreamlak TW, Gebremeskel TT, Adde BL, et al
    Determinants of post-acute COVID-19 syndrome among hospitalized severe COVID-19 patients: A 2-year follow-up study.
    PLoS One. 2024;19:e0298409.
    PubMed         Abstract available
    
51. PALL T, Abroi A, Avi R, Niglas H, et al
    SARS-CoV-2 clade dynamics and their associations with hospitalisations during the first two years of the COVID-19 pandemic.
    PLoS One. 2024;19:e0303176.
    PubMed         Abstract available
    
52. RAMOS A, Martins S, Marinho AS, Norton P, et al
    Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers.
    PLoS One. 2024;19:e0303244.
    PubMed         Abstract available
    
53. TO T, Zhu J, Terebessy E, Borkhoff CM, et al
    Mode of delivery and birth outcomes before and during COVID-19 -A population-based study in Ontario, Canada.
    PLoS One. 2024;19:e0303175.
    PubMed         Abstract available
    
54. VINDEIRINHO JM, Oliveira R, Pinho E, Guiomar R, et al
    The potential of tailed amplicons for SARS-CoV-2 detection in Nucleic Acid Lateral Flow Assays.
    PLoS One. 2024;19:e0301234.
    PubMed         Abstract available
    
55. MARTELL M, Terry N, Sengupta R, Salazar C, et al
    Open-source data pipeline for street-view images: A case study on community mobility during COVID-19 pandemic.
    PLoS One. 2024;19:e0303180.
    PubMed         Abstract available
    
56. BAUTISTA-ARREDONDO LF, Munoz-Rocha TV, Figueroa JL, Tellez-Rojo MM, et al
    A surge in food insecurity during the COVID-19 pandemic in a cohort in Mexico City.
    PLoS One. 2024;19:e0297694.
    PubMed         Abstract available
    
57. YASOPA O, Homkham N, Chompook P
    Factors affecting the number of influenza patients before and during COVID-19 pandemic, Thailand.
    PLoS One. 2024;19:e0303382.
    PubMed         Abstract available
    
58. FERDOUS MZ, Islam MS, Kundu LR, Islam US, et al
    Patterns of eating behaviors, physical activity, and lifestyle modifications among Bangladeshi adolescents during the COVID-19 pandemic.
    PLoS One. 2024;19:e0302571.
    PubMed         Abstract available
    
59. CHEN N, Wang R, Zhu W, Hao X, et al
    Development and characterization of an antibody that recognizes influenza virus N1 neuraminidases.
    PLoS One. 2024;19:e0302865.
    PubMed         Abstract available
    
60. KERN M, Glatz T, Mall MA, Seybold J, et al
    Health-related quality of life and impact of socioeconomic status among primary and secondary school students after the third COVID-19 wave in Berlin, Germany.
    PLoS One. 2024;19:e0302995.
    PubMed         Abstract available
    
61. NOUR D, Ismail MB, Osman M, Rafei R, et al
    Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon.
    PLoS One. 2024;19:e0302579.
    PubMed         Abstract available
    
    
    Proc Natl Acad Sci U S A
62. MORALES M, Yang MY, Goddard WA 3rd, Gray HB, et al
    Copper(II) coordination to the intrinsically disordered region of SARS-CoV-2 Nsp1.
    Proc Natl Acad Sci U S A. 2024;121:e2402653121.
    PubMed         Abstract available
    
    
    Vaccine
63. WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
    A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
64. EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
    Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
    Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
65. BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
    Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
    Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
66. MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
    Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
    Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
67. SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
    Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
68. KIM J, Chang J
    Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
    Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
69. KIM DH, Lee SH, Kim J, Lee J, et al
    Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
    Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
    Virus Res
70. WU CC, Tam EH, Shih YY, Lin YR, et al
    Exploration of influenza A virus PA protein-associated cellular proteins discloses its impact on mitochondrial function.
    Virus Res. 2024 May 6:199387. doi: 10.1016/j.virusres.2024.199387.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, May 4 ’24)

1. GRADY E, Pattison DA, Redman S, Satoh Y, et al
   The Global Reading Room: Performing a Ventilation-Perfusion Study in a Patient With Recent COVID-19.
   AJR Am J Roentgenol. 2024 May 1. doi: 10.2214/AJR.24.31348.
   PubMed        
   
   
   Am J Obstet Gynecol
2. MAGNUS MC, Rasmussen TD, Ortqvist AK, Oakley LL, et al
   Covid-19 vaccination during pregnancy is not associated with an increased risk of severe post-partum hemorrhage.
   Am J Obstet Gynecol. 2024 Apr 30:S0002-9378(24)00554.
   PubMed        
   
   
   Am J Respir Crit Care Med
3. AZOULAY E, Pochard F, Argaud L, Kentish-Barnes N, et al
   Reply to Zijlstra: Resilience and Stress Are Heterogenic Too, We Should Act Accordingly.
   Am J Respir Crit Care Med. 2024 May 3. doi: 10.1164/rccm.202404-0790.
   PubMed        
   
   
   Antiviral Res
4. LIU X, Wang Y, Sun L, Xiao G, et al
   Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
   Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
   PubMed         Abstract available
   
5. ARDUINO I, Francese R, Civra A, Feyles E, et al
   Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
   Antiviral Res. 2024;226:105897.
   PubMed         Abstract available
   
6. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
   SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
   Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
   PubMed         Abstract available
   
   
   BMJ
7. SILLETT JM
   Perhaps politicians and health leaders could #sayhellotopatients?
   BMJ. 2024;385:q976.
   PubMed        
   
8. MATHEW R
   Rammya Mathew: We can’t overlook the backdrop as Britain becomes “a sicker nation”.
   BMJ. 2024;385:q956.
   PubMed        
   
9. WISE J
   MP resigns from Tory party over NHS “stretched close to breaking point”.
   BMJ. 2024;385:q983.
   PubMed        
   
10. MIDDLETON J, Saunders P
    What will it take for a new sanitary revolution in the UK?
    BMJ. 2024;385:q974.
    PubMed        
    
11. MORGAN SG
    When will Canada have national pharmacare?
    BMJ. 2024;385:q887.
    PubMed        
    
12. TANNE JH
    US pregnant workers get new legal protections, but not paid time off.
    BMJ. 2024;385:q926.
    PubMed        
    
13. MAHASE E
    Doctors will shape Labour’s 10 year plan to fix NHS crisis, says shadow health secretary.
    BMJ. 2024;385:q980.
    PubMed        
    
14. MCCARTNEY M, Liu PJ, Fearfull A, Macdonald H, et al
    Early diagnosis is not always an unmitigated good, we need to make it useful for patients and clinicians.
    BMJ. 2024;385:q973.
    PubMed        
    
15. 
    Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial.
    BMJ. 2024;385:q988.
    PubMed        
    
16. LANG K
    What do we know about covid-19’s effects on the gut?
    BMJ. 2024;385:q842.
    PubMed        
    
17. 
    Seven days in medicine: 24-30 April 2024.
    BMJ. 2024;385:q969.
    PubMed        
    
    
    Br J Anaesth
18. BOWDLE A, Brosseau LM, Tellier R, MacIntyre CR, et al
    Reducing airborne transmissible diseases in perioperative environments.
    Br J Anaesth. 2024 Apr 26:S0007-0912(24)00181-8. doi: 10.1016/j.bja.2024.
    PubMed         Abstract available
    
    
    Clin Infect Dis
19. JORGENSEN SCJ, Brown K, Clarke AE, Schwartz KL, et al
    The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study.
    Clin Infect Dis. 2024 May 3:ciae182. doi: 10.1093.
    PubMed         Abstract available
    
20. BRAMANTE CT, Beckman KB, Mehta T, Karger AB, et al
    Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019.
    Clin Infect Dis. 2024 May 1:ciae159. doi: 10.1093.
    PubMed         Abstract available
    
21. SIEDNER MJ, Sax PE
    Repurposing Revisited: Exploring the Role of Metformin for Treatment of Coronavirus Disease 2019.
    Clin Infect Dis. 2024 May 1:ciae154. doi: 10.1093.
    PubMed        
    
22. 
    Correction to: Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients.
    Clin Infect Dis. 2024 Apr 30:ciae164. doi: 10.1093.
    PubMed        
    
23. 
    Correction to: Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology.
    Clin Infect Dis. 2024 Apr 30:ciae166. doi: 10.1093.
    PubMed        
    
    
    Int J Infect Dis
24. XIE H, Zhang J, Bai S, Lv M, et al
    The contributions of vaccination and natural infection to the production of neutralizing antibodies against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prototype strain and variants.
    Int J Infect Dis. 2024 Apr 24:107060. doi: 10.1016/j.ijid.2024.107060.
    PubMed         Abstract available
    
25. MARTINEZ-FIERRO ML, Perez-Favila A, Alfaro SMZ, Oropeza-de Lara SA, et al
    Gene variants rs5182, rs2074192, and rs4343 in the Renin-Angiotensin-Aldosterone system are associated with symptom severity, higher odds of hospitalization, and death in COVID-19.
    Int J Infect Dis. 2024 Apr 30:107067. doi: 10.1016/j.ijid.2024.107067.
    PubMed         Abstract available
    
26. YAN X, Zhao X, Du Y, Wang H, et al
    Dynamics of anti-SARS-CoV-2 IgG antibody responses following breakthrough infection and the predicted protective efficacy: a longitudinal community-based population study in China.
    Int J Infect Dis. 2024 Apr 30:107075. doi: 10.1016/j.ijid.2024.107075.
    PubMed         Abstract available
    
27. MURRAY HC, Muleme M, Cooper D, McNamara BJ, et al
    Prevalence, risk factors and outcomes of secondary infections among hospitalised patients with COVID-19 or post-COVID-19 conditions in Victoria, 2020-2023.
    Int J Infect Dis. 2024 Apr 30:107078. doi: 10.1016/j.ijid.2024.107078.
    PubMed         Abstract available
    
    
    J Med Virol
28. ZHAO XJ, Liu XL, Liang YM, Zhang S, et al
    Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    J Med Virol. 2024;96:e29640.
    PubMed         Abstract available
    
29. TANG Z, Mao Y, Ruan P, Li J, et al
    Drugs targeting CMPK2 inhibit pyroptosis to alleviate severe pneumonia caused by multiple respiratory viruses.
    J Med Virol. 2024;96:e29643.
    PubMed         Abstract available
    
30. MATUSALI G, Mazzotta V, Meschi S, Colavita F, et al
    JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.
    J Med Virol. 2024;96:e29631.
    PubMed        
    
31. GAO R, Feng C, Sheng Z, Li F, et al
    Research progress in Fc-effector functions against SARS-CoV-2.
    J Med Virol. 2024;96:e29638.
    PubMed         Abstract available
    
32. WANG F, Gao Y, Wagner AL, Lu Y, et al
    A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination.
    J Med Virol. 2024;96:e29629.
    PubMed         Abstract available
    
33. THOMAS S, Smatti MK, Alsulaiti H, Zedan HT, et al
    Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens.
    J Med Virol. 2024;96:e29628.
    PubMed         Abstract available
    
    
    Lancet
34. GREEN A
    Tobias Welte.
    Lancet. 2024;403:1626.
    PubMed        
    
35. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    PubMed        
    
36. MARCHALIK D, Rehm D
    On not cutting corners.
    Lancet. 2024;403:1623.
    PubMed        
    
    
    Lancet Infect Dis
37. KEDDY KH, Tadesse BT
    Inaccessible: health, wealth, governance, and equity in low-income and middle-income countries.
    Lancet Infect Dis. 2024;24:444-445.
    PubMed        
    
38. KOCHER K, Moosmann C, Drost F, Schulein C, et al
    Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual.
    Lancet Infect Dis. 2024;24:e272-e274.
    PubMed        
    
39. LIN DY, Huang S, Milinovich A, Duggal A, et al
    Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA.
    Lancet Infect Dis. 2024;24:e278-e280.
    PubMed        
    
40. DE AMBROGI M
    A summer cold.
    Lancet Infect Dis. 2024;24:461.
    PubMed        
    
41. KAZI F, Mushtaq A
    Nuria Izquierdo-Useros-fighting the good fight.
    Lancet Infect Dis. 2024;24:458.
    PubMed        
    
42. MOODY J
    On the frontline during the COVID-19 pandemic.
    Lancet Infect Dis. 2024;24:464.
    PubMed        
    
43. VISSER LG
    Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape.
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00254.
    PubMed        
    
44. WONGNAK P, Schilling WHK, Jittamala P, Boyd S, et al
    Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00183.
    PubMed         Abstract available
    
45. VENKATESAN P
    Tobias Welte.
    Lancet Infect Dis. 2024;24:457.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
46. XIE AG, Yomogida K, Berry I, Briggs NL, et al
    Notes from the Field: Increase in Nontoxigenic Corynebacterium diphtheriae – Washington, 2018-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:405-407.
    PubMed        
    
    
    Nature
47. CALLAWAY E
    Scientists tried to give people COVID – and failed.
    Nature. 2024 May 1. doi: 10.1038/d41586-024-01284.
    PubMed        
    
48. MALLAPATY S
    Chinese virologist who was first to share COVID-19 genome sleeps on street after lab shuts.
    Nature. 2024 May 1. doi: 10.1038/d41586-024-01293.
    PubMed        
    
49. LENHARO M, Wolf L
    Controversial virus-hunting scientist skewered at US COVID-origins hearing.
    Nature. 2024 May 1. doi: 10.1038/d41586-024-01305.
    PubMed        
    
    
    Radiology
50. SUTHAR PP, Hughes K, Mafraji M, Akyuz M, et al
    Case 324: CHANTER Syndrome.
    Radiology. 2024;311:e222748.
    PubMed         Abstract available
    
    
    Science
51. CICERO A, Phelan A
    A pandemic agreement is within reach.
    Science. 2024;384:489.
    PubMed         Abstract available
    
52. LYNTERIS C
    Pandemics and their accelerantsThe Human Disease: How We Create Pandemics, from Our Bodies to Our Beliefs Sabrina Sholts MIT Press, 2024. 352 pp.
    Science. 2024;384:517.
    PubMed         Abstract available

#Influenza and #COVID19 Research #References (by Amedeo.com, May 4 ’24)

1. LU A, Chen CC, Lin C, Wu TJ, et al
   Artificial Intelligence Electrocardiography Detecting Thyrotoxic Periodic Paralysis Following a SARS-CoV-2 Infection.
   Am J Med. 2024 Jan 25:S0002-9343(24)00054-8. doi: 10.1016/j.amjmed.2024.
   PubMed        
   
   
   Antimicrob Agents Chemother
2. CLEGG LE, Stepanov O, Schmidt H, Tang W, et al
   Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
   Antimicrob Agents Chemother. 2024;68:e0158723.
   PubMed         Abstract available
   
   
   Biochem Biophys Res Commun
3. KAWAI A, Hirata H, Tokunoh N, Ono C, et al
   Adjuvant-free parenterally injectable vaccine platform that harnesses previously induced IgG as an antigen delivery carrier.
   Biochem Biophys Res Commun. 2024;711:149919.
   PubMed         Abstract available
   
4. BAI G, Zeng X, Zhang L, Wang Y, et al
   Computational investigation of the inhibitory interaction of IRF3 and SARS-CoV-2 accessory protein ORF3b.
   Biochem Biophys Res Commun. 2024;712-713:149945.
   PubMed         Abstract available
   
5. KOMU JG, Jamsransuren D, Matsuda S, Ogawa H, et al
   Collection and transportation of SARS-CoV-2 and influenza A virus diagnostic samples: Optimizing the usage of guanidine-based chaotropic salts for enhanced biosafety and viral genome preservation.
   Biochem Biophys Res Commun. 2024;715:149994.
   PubMed         Abstract available
   
   
   BMC Pediatr
6. OGILVIE RP, Layton JB, Lloyd PC, Jiao Y, et al
   Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study.
   BMC Pediatr. 2024;24:276.
   PubMed         Abstract available
   
   
   BMJ
7. 
   Seven days in medicine: 24-30 April 2024.
   BMJ. 2024;385:q969.
   PubMed        
   
8. LANG K
   What do we know about covid-19’s effects on the gut?
   BMJ. 2024;385:q842.
   PubMed        
   
9. MCCARTNEY M, Liu PJ, Fearfull A, Macdonald H, et al
   Early diagnosis is not always an unmitigated good, we need to make it useful for patients and clinicians.
   BMJ. 2024;385:q973.
   PubMed        
   
10. TANNE JH
    US pregnant workers get new legal protections, but not paid time off.
    BMJ. 2024;385:q926.
    PubMed        
    
11. MAHASE E
    Doctors will shape Labour’s 10 year plan to fix NHS crisis, says shadow health secretary.
    BMJ. 2024;385:q980.
    PubMed        
    
12. SILLETT JM
    Perhaps politicians and health leaders could #sayhellotopatients?
    BMJ. 2024;385:q976.
    PubMed        
    
13. MATHEW R
    Rammya Mathew: We can’t overlook the backdrop as Britain becomes “a sicker nation”.
    BMJ. 2024;385:q956.
    PubMed        
    
14. WISE J
    MP resigns from Tory party over NHS “stretched close to breaking point”.
    BMJ. 2024;385:q983.
    PubMed        
    
15. MIDDLETON J, Saunders P
    What will it take for a new sanitary revolution in the UK?
    BMJ. 2024;385:q974.
    PubMed        
    
16. MORGAN SG
    When will Canada have national pharmacare?
    BMJ. 2024;385:q887.
    PubMed        
    
    
    Epidemiol Infect
17. CHAMBERS T, Anglemyer A, Chen A, Atkinson J, et al
    Population and contact tracer uptake of New Zealand’s QR-code-based digital contact tracing app for COVID-19.
    Epidemiol Infect. 2024;152:e66.
    PubMed         Abstract available
    
    
    J Gen Virol
18. AHRENS AK, Jonsson SR, Svansson V, Brugger B, et al
    Iceland: an underestimated hub for the spread of high-pathogenicity avian influenza viruses in the North Atlantic.
    J Gen Virol. 2024;105.
    PubMed         Abstract available
    
    
    J Infect
19. CANE J, Sanderson N, Barnett S, Vaughan A, et al
    Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022-23.
    J Infect. 2024 Apr 29:106164. doi: 10.1016/j.jinf.2024.106164.
    PubMed         Abstract available
    
20. PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al
    Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance.
    J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153.
    PubMed         Abstract available
    
21. CAINI S, Casalegno JS, Rodrigues AP, Lee V, et al
    Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national study.
    J Infect. 2024;88:106154.
    PubMed         Abstract available
    
22. COLSON P, Chaudet H, Delerce J, Pontarotti P, et al
    Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic.
    J Infect. 2024 Apr 1:106150. doi: 10.1016/j.jinf.2024.106150.
    PubMed         Abstract available
    
23. GAYLIS NB, Yang OO
    Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC) – The hunt for effective treatments.
    J Infect. 2024 Mar 24:106146. doi: 10.1016/j.jinf.2024.106146.
    PubMed        
    
24. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    PubMed        
    
25. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    PubMed         Abstract available
    
    
    J Infect Dis
26. BI Q, Dickerman BA, Nguyen HQ, Martin ET, et al
    Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection.
    J Infect Dis. 2024 Apr 30:jiae220. doi: 10.1093.
    PubMed         Abstract available
    
    
    J Virol Methods
27. KRUNKOSKY M, Krunkosky TM, Meliopoulos V, Kyriakis CS, et al
    Establishment of Swine Primary Nasal, Tracheal, and Bronchial Epithelial Cell Culture Models for the Study of Influenza Virus Infection.
    J Virol Methods. 2024 Apr 26:114943. doi: 10.1016/j.jviromet.2024.114943.
    PubMed         Abstract available
    
28. AN SH, Kim NY, Heo GB, Kang YM, et al
    Development and evaluation of a multiplex real-time RT-PCR assay for simultaneous detection of H5, H7, and H9 subtype avian influenza viruses.
    J Virol Methods. 2024;327:114942.
    PubMed         Abstract available
    
    
    Lancet
29. MARCHALIK D, Rehm D
    On not cutting corners.
    Lancet. 2024;403:1623.
    PubMed        
    
30. GREEN A
    Tobias Welte.
    Lancet. 2024;403:1626.
    PubMed        
    
    
    N Engl J Med
31. UYEKI TM, Milton S, Abdul Hamid C, Reinoso Webb C, et al
    Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Dairy Farm Worker.
    N Engl J Med. 2024 May 3. doi: 10.1056/NEJMc2405371.
    PubMed        
    
    
    Pediatrics
32. DEWALD F, Steger G, Fish I, Torre-Lage I, et al
    SARS-CoV-2 Test-to-Stay in Daycare.
    Pediatrics. 2024;153:e2023064668.
    PubMed         Abstract available
    
33. SENTER JP, Aisenberg LK, Dudley JW, Luan X, et al
    COVID-19 and Asthma Onset in Children.
    Pediatrics. 2024 Apr 12:e2023064615. doi: 10.1542/peds.2023-064615.
    PubMed         Abstract available
    
34. SAPER JK, Heffernan M, Simon NE, Davis MM, et al
    RSV Vaccination Intention Among People Who Are or Plan to Become Pregnant.
    Pediatrics. 2024 Apr 25:e2023065140. doi: 10.1542/peds.2023-065140.
    PubMed         Abstract available
    
    
    PLoS Med
35. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    PubMed         Abstract available
    
    
    PLoS One
36. CHEN C, Martins M, Nooruzzaman M, Yettapu D, et al
    Spatial and temporal clustering of anti-SARS-CoV-2 antibodies in Illinois household cats, 2021-2023.
    PLoS One. 2024;19:e0299388.
    PubMed         Abstract available
    
37. HUA MJ, Butera G, Akinyemi O, Porterfield D, et al
    Biases and limitations in observational studies of Long COVID prevalence and risk factors: A rapid systematic umbrella review.
    PLoS One. 2024;19:e0302408.
    PubMed         Abstract available
    
38. CHIRAPAPAISAN N, Eiamsamarng A, Chuenkongkaew W, Rattanathamsakul N, et al
    The prone position in COVID-19 impacts the thickness of peripapillary retinal nerve fiber layers and macular ganglion cell layers.
    PLoS One. 2024;19:e0300621.
    PubMed         Abstract available
    
39. YUSPAHRUDDIN A, Abbas H, Pahala I, Eliyana A, et al
    Fostering proactive work behavior: Where to start?
    PLoS One. 2024;19:e0298936.
    PubMed         Abstract available
    
40. AMIO MGA, Ahmed HN, Ali SM, Ahmed S, et al
    Key determinants to supply chain resilience to face pandemic disruption: An interpretive triple helix framework.
    PLoS One. 2024;19:e0299778.
    PubMed         Abstract available
    
41. YUAN JL, Jing N
    The financial risk of real estate combined factor analysis with grey prediction in Liaoning Province.
    PLoS One. 2024;19:e0301526.
    PubMed         Abstract available
    
42. DEWI PEN, Sunantiwat M, Thavorncharoensap M, Youngkong S, et al
    Treatment seeking experiences of ACS patients in Yogyakarta, Indonesia during COVID-19 pandemic: A qualitative study.
    PLoS One. 2024;19:e0302320.
    PubMed         Abstract available
    
43. ASUMADU ODK, Boah M, Chirawurah D, Ndago JA, et al
    Pregnancy outcomes before and during COVID-19 pandemic in Tamale Metropolis, Ghana: A retrospective cohort study.
    PLoS One. 2024;19:e0302589.
    PubMed         Abstract available
    
44. ZHOU X, Huang T, Pan H, Du A, et al
    Bioinformatics and system biology approaches to determine the connection of SARS-CoV-2 infection and intrahepatic cholangiocarcinoma.
    PLoS One. 2024;19:e0300441.
    PubMed         Abstract available
    
45. MARTINS P, Luzia RWS, Filho JAP, Welsh KS, et al
    Prevalence and factors associated with burnout among health professionals of a public hospital network during the COVID-19 pandemic.
    PLoS One. 2024;19:e0298187.
    PubMed         Abstract available
    
46. VRABCOVA P, Scholz P, Linderova I, Kotouckova H, et al
    Eco-friendly hotels and guesthouses as a new opportunity for resilience and sustainability: Evidence from the Czech Republic.
    PLoS One. 2024;19:e0301936.
    PubMed         Abstract available
    
47. HALL V, Cardona C, Mendoza K, Torchetti M, et al
    Surveillance for highly pathogenic avian influenza A (H5N1) in a raptor rehabilitation center-2022.
    PLoS One. 2024;19:e0299330.
    PubMed         Abstract available
    
48. TAMARGO JA, Martin HR, Diaz-Martinez J, Delgado-Enciso I, et al
    Drug use and COVID-19 testing, vaccination, and infection among underserved, minority communities in Miami, Florida.
    PLoS One. 2024;19:e0297327.
    PubMed         Abstract available
    
49. YAMAJI T, Harada T, Hashimoto Y, Nakano Y, et al
    Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function.
    PLoS One. 2024;19:e0302512.
    PubMed         Abstract available
    
50. HWANG LA, Vaithilingam S, Ng JWJ, Nair M, et al
    The continuance intention to vaccinate against COVID-19: An empirical study from Malaysia.
    PLoS One. 2024;19:e0301383.
    PubMed         Abstract available
    
51. WEIGOLD S, Schorr SG, Faust A, Woydack L, et al
    Informed consent and trial prioritization for clinical studies during the COVID-19 pandemic. Stakeholder experiences and viewpoints.
    PLoS One. 2024;19:e0302755.
    PubMed         Abstract available
    
52. JANNAT Z, Das H, Ali MW, Wahed T, et al
    Disparities in COVID-19 vaccine uptake among rural hard-to-reach population and urban high-risk groups of Bangladesh.
    PLoS One. 2024;19:e0302056.
    PubMed         Abstract available
    
53. ZHANG R, Byrd T, Qiao S, Torres ME, et al
    Maternal care utilization and provision during the COVID-19 pandemic: Voices from minoritized pregnant and postpartum women and maternal care providers in Deep South.
    PLoS One. 2024;19:e0300424.
    PubMed         Abstract available
    
54. DAVINA-NUNEZ C, Perez S, Cabrera-Alvargonzalez JJ, Rincon-Quintero A, et al
    Performance of amplicon and capture based next-generation sequencing approaches for the epidemiological surveillance of Omicron SARS-CoV-2 and other variants of concern.
    PLoS One. 2024;19:e0289188.
    PubMed         Abstract available
    
55. ESPER TREML R, Caldonazo T, Barlem Hohmann F, Lima da Rocha D, et al
    Association of chest computed tomography severity score at ICU admission and respiratory outcomes in critically ill COVID-19 patients.
    PLoS One. 2024;19:e0299390.
    PubMed         Abstract available
    
56. HU Y, Villalan AK, Fan X, Zhang S, et al
    Analysis the molecular similarity of least common amino acid sites in ACE2 receptor to predict the potential susceptible species for SARS-CoV-2.
    PLoS One. 2024;19:e0293441.
    PubMed         Abstract available
    
57. ASSCHE SB, Ferraccioli F, Riccetti N, Gomez-Ramirez J, et al
    Urban-rural disparities in COVID-19 hospitalisations and mortality: A population-based study on national surveillance data from Germany and Italy.
    PLoS One. 2024;19:e0301325.
    PubMed         Abstract available
    
58. ZOZMANN H, Schuler L, Fu X, Gawel E, et al
    Autonomous and policy-induced behavior change during the COVID-19 pandemic: Towards understanding and modeling the interplay of behavioral adaptation.
    PLoS One. 2024;19:e0296145.
    PubMed         Abstract available
    
59. KELEYNIKOV M, Cohen N, Benatov J
    Maternal distress during the COVID-19 outbreak: A socio-ecological perspective.
    PLoS One. 2024;19:e0302266.
    PubMed         Abstract available
    
60. CHUEMCHIT M, Linn N, Han CPP, Lynn Z, et al
    Discrimination and violence against women migrant workers in Thailand during the COVID-19 pandemic: A mixed-methods study.
    PLoS One. 2024;19:e0300388.
    PubMed         Abstract available
    
61. ZOU Y, Pan M, Zhou T, Yan L, et al
    Critical COVID-19, Victivallaceae abundance, and celiac disease: A mediation Mendelian randomization study.
    PLoS One. 2024;19:e0301998.
    PubMed         Abstract available
    
62. NEWMAN PA, Chakrapani V, Massaquoi N, Williams CC, et al
    Effectiveness of an eHealth intervention for reducing psychological distress and increasing COVID-19 knowledge and protective behaviors among racialized sexual and gender minority adults: A quasi-experimental study (#SafeHandsSafeHearts).
    PLoS One. 2024;19:e0280710.
    PubMed         Abstract available
    
63. CASJENS S, Taeger D, Bruning T, Behrens T, et al
    Changes in mental distress among employees during the three years of the COVID-19 pandemic in Germany.
    PLoS One. 2024;19:e0302020.
    PubMed         Abstract available
    
    
    Proc Natl Acad Sci U S A
64. MAO T, Kim J, Pena-Hernandez MA, Valle G, et al
    Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract.
    Proc Natl Acad Sci U S A. 2024;121:e2319566121.
    PubMed         Abstract available
    
65. KUNG CSJ, Steptoe A
    Changes in well-being among socially isolated older people during the COVID-19 pandemic: An outcome-wide analysis.
    Proc Natl Acad Sci U S A. 2024;121:e2308697121.
    PubMed         Abstract available
    
    
    Vaccine
66. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    PubMed        
    
67. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
68. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
69. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
70. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
71. EJNAR HANSEN M, David Pickering S
    The role of religion and COVID-19 vaccine uptake in England.
    Vaccine. 2024;42:3215-3219.
    PubMed         Abstract available
    
72. FLEARY SA, Shahn Z, Teasdale CA
    Effects of parental childhood cultural health environment on children’s influenza and COVID-19 vaccination status.
    Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
    Virology
73. MA X, Wang Q, Xu X, Zhang W, et al
    miR-214-PTEN pathway is a potential mechanism for stress-induced immunosuppression affecting chicken immune response to avian influenza virus vaccine.
    Virology. 2024;595:110094.
    PubMed         Abstract available
    
74. KIM KH, Bhatnagar N, Subbiah J, Liu R, et al
    Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.
    Virology. 2024;595:110097.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 27 ’24)

1. PAXTON JH, Keenan KJ, Wilburn JM, Wise SL, et al
   Headpulse measurement can reliably identify large-vessel occlusion stroke in prehospital suspected stroke patients: Results from the EPISODE-PS-COVID study.
   Acad Emerg Med. 2024 Apr 21. doi: 10.1111/acem.14919.
   PubMed         Abstract available
   
   
   Antiviral Res
2. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
   Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
   Antiviral Res. 2024;226:105891.
   PubMed         Abstract available
   
   
   BMJ
3. 
   Seven days in medicine: 17-23 April 2024.
   BMJ. 2024;385:q924.
   PubMed        
   
4. KANG D
   The ever looming shadow of caregiving.
   BMJ. 2024;385:q726.
   PubMed        
   
5. LAUNER J
   John Launer: Doctors as activists.
   BMJ. 2024;385:q939.
   PubMed        
   
   
   Clin Infect Dis
6. CHUA KP, Fischer MA, Rahman M, Linder JA, et al
   Changes in the Appropriateness of US Outpatient Antibiotic Prescribing After the Coronavirus Disease 2019 Outbreak: An Interrupted Time Series Analysis of 2016-2021 Data.
   Clin Infect Dis. 2024 Apr 22:ciae135. doi: 10.1093.
   PubMed         Abstract available
   
7. VASCONCELOS A, King JD, Nunes-Alves C, Anderson R, et al
   Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?
   Clin Infect Dis. 2024;78.
   PubMed         Abstract available
   
   
   Emerg Infect Dis
8. OPE M, Musyoka R, Kiogora J, Wambugu J, et al
   Epidemiology of SARS-CoV-2 in Kakuma Refugee Camp Complex, Kenya, 2020-2021(1).
   Emerg Infect Dis. 2024;30:900-907.
   PubMed         Abstract available
   
9. NOBLE BA, Jiudice SS, Jones JD, Timbrook TT, et al
   Reemergence of Bordetella parapertussis, United States, 2019-2023.
   Emerg Infect Dis. 2024;30:1058-1060.
   PubMed         Abstract available
   
10. YEE R, Carranza D, Kim C, Trinidad JP, et al
    COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022.
    Emerg Infect Dis. 2024;30:947-955.
    PubMed         Abstract available
    
11. KEHOE AD, Mallhi AK, Barton CR, Martin HM, et al
    SARS-CoV-2 Transmission in Alberta, British Columbia, and Ontario, Canada, January 2020-January 2022.
    Emerg Infect Dis. 2024;30:956-967.
    PubMed         Abstract available
    
12. MOUCHTOURI VA, Kourentis L, Anagnostopoulos L, Koureas M, et al
    Interventional Study of Nonpharmaceutical Measures to Prevent COVID-19 Aboard Cruise Ships.
    Emerg Infect Dis. 2024;30:1030-1033.
    PubMed         Abstract available
    
13. LUSTIG Y, Canetti M, Indenbaum V, Peretz Y, et al
    SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023.
    Emerg Infect Dis. 2024;30:1050-1052.
    PubMed         Abstract available
    
14. NGUYENLA XH, Bates TA, Trank-Greene M, Wahedi M, et al
    Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine.
    Emerg Infect Dis. 2024;30.
    PubMed         Abstract available
    
15. DOI A, Ota M, Saito M, Matsuyama S, et al
    Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
    Emerg Infect Dis. 2024;30.
    PubMed         Abstract available
    
    
    Infect Control Hosp Epidemiol
16. TAN C, Chan CK, Ofner M, O’Brien J, et al
    Implementation of point-of-care molecular testing for respiratory viruses in congregate living settings.
    Infect Control Hosp Epidemiol. 2024 Apr 25:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
    
    Int J Infect Dis
17. VERGORI A, Cozzi-Lepri A, Tavelli A, Mazzotta V, et al
    SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T cell counts in people living with HIV.
    Int J Infect Dis. 2024 Apr 19:107065. doi: 10.1016/j.ijid.2024.107065.
    PubMed         Abstract available
    
    
    J Infect
18. ZHOU J, Lan L, Ai S, Lin J, et al
    Corrigendum to: “People living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention” Journal of Infection, Volume 88, Issue 3, March 2024, 106122.
    J Infect. 2024 Apr 24:106157. doi: 10.1016/j.jinf.2024.106157.
    PubMed        
    
    
    J Med Virol
19. HSU AY, Lin CJ, Hsia NY, Wang YH, et al
    Reply to comment on “The risk assessment of uveitis after COVID-19 diagnosis by Wu et al. 2024”.
    J Med Virol. 2024;96:e29636.
    PubMed        
    
20. HEWEL C, Schmidt H, Runkel S, Kohnen W, et al
    Nanopore adaptive sampling of a metagenomic sample derived from a human monkeypox case.
    J Med Virol. 2024;96:e29610.
    PubMed         Abstract available
    
21. SONG G, Li R, Cheng MQ
    Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.
    J Med Virol. 2024;96:e29625.
    PubMed         Abstract available
    
    
    J Virol
22. VIOX EG, Bosinger SE, Douek DC, Schreiber G, et al
    Harnessing the power of IFN for therapeutic approaches to COVID-19.
    J Virol. 2024 Apr 23:e0120423. doi: 10.1128/jvi.01204.
    PubMed         Abstract available
    
23. MAO D, Liu S, Phan AT, Renner S, et al
    The TRAF3-DYRK1A-RAD54L2 complex maintains ACE2 expression to promote SARS-CoV-2 infection.
    J Virol. 2024 Apr 23:e0034724. doi: 10.1128/jvi.00347.
    PubMed         Abstract available
    
    
    JAMA
24. HARRIS E
    Antidepressant Prescriptions for Female Teens Surged After Pandemic.
    JAMA. 2024;331:1266.
    PubMed        
    
25. BARNELL EK, Lieberman DA
    Multitarget Stool RNA Testing-Reply.
    JAMA. 2024;331:1419-1420.
    PubMed        
    
26. BAIRD G
    Multitarget Stool RNA Testing.
    JAMA. 2024;331:1418-1419.
    PubMed        
    
27. IMPERIALE TF, Lavin P, Ransohoff DF
    Multitarget Stool RNA Testing.
    JAMA. 2024;331:1418.
    PubMed        
    
28. HARRIS E
    Deaths From Excessive Drinking Rose in the US During Pandemic.
    JAMA. 2024;331:1355.
    PubMed        
    
29. HARRIS E
    Meta-Analysis: “Limited” Benefits to Rapid Viral Tests in EDs.
    JAMA. 2024;331:1355.
    PubMed        
    
30. ALLEN MR, Desai N, Namazi A, Leas E, et al
    Characteristics of X (Formerly Twitter) Community Notes Addressing COVID-19 Vaccine Misinformation.
    JAMA. 2024 Apr 24:e244800. doi: 10.1001/jama.2024.4800.
    PubMed        
    
31. HARRIS E
    WHO Launches Broad Coronavirus Surveillance Network.
    JAMA. 2024 Apr 26. doi: 10.1001/jama.2024.6724.
    PubMed        
    
    
    Lancet
32. DEVI S
    Swedish NGOs are reeling after government cuts.
    Lancet. 2024;403:1527.
    PubMed        
    
33. 
    Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a sys
    Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757.
    PubMed         Abstract available
    
    
    Lancet Infect Dis
34. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    PubMed         Abstract available
    
35. ZUO W, He D, Liang C, Du S, et al
    The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00171.
    PubMed         Abstract available
    
36. BUONSENSO D, Tantisira KG
    Long COVID and SARS-CoV-2 persistence: new answers, more questions.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00216.
    PubMed        
    
    
    Life Sci
37. LI Q, Peng G, Liu H, Wang L, et al
    Molecular mechanisms of secretory autophagy and its potential role in diseases.
    Life Sci. 2024 Apr 23:122653. doi: 10.1016/j.lfs.2024.122653.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
38. PANAGIOTAKOPOULOS L, Godfrey M, Moulia DL, Link-Gelles R, et al
    Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged >/=65 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:377-381.
    PubMed         Abstract available
    
39. SMITH-JEFFCOAT SE, Mellis AM, Grijalva CG, Talbot HK, et al
    SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance – Respiratory Virus Transmission Network, November 2022-May 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:365-371.
    PubMed         Abstract available
    
    
    N Engl J Med
40. MOSER CB, Li JZ, Hughes MD
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1533-1534.
    PubMed        
    
41. SELVI-SABATER P, de la Rubia Orti JE, Urbieta-Sanz E
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1534.
    PubMed        
    
42. WANG Y, Hu H, Cao B
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply.
    N Engl J Med. 2024;390:1534-1535.
    PubMed        
    
    
    Nature
43. NOGRADY B
    WHO redefines airborne transmission: what does that mean for future pandemics?
    Nature. 2024 Apr 24. doi: 10.1038/d41586-024-01173.
    PubMed        
    
    
    Radiologia (Engl Ed)
44. PLASENCIA MARTINEZ JM, Garcia Tuells I, Bravo Perez C, Blanco Barrio A, et al
    Target sign in COVID-19, radiological interpretation and diagnostic contribution of digital thoracic tomosynthesis.
    Radiologia (Engl Ed). 2024;66 Suppl 1:S32-S39.
    PubMed         Abstract available
    
45. VALENZUELA C, de la Fuente L, Hernandez S, Olivera MJ, et al
    Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia.
    Radiologia (Engl Ed). 2024;66 Suppl 1:S47-S56.
    PubMed         Abstract available
    
    
    Science
46. COHEN J
    Africa steps up battle against mpox outbreaks.
    Science. 2024;384:373-374.
    PubMed         Abstract available

#Influenza and #COVID19 Research #References (by Amedeo.com, April 27 ’24)

1. TARE DS, Keng SS, Walimbe AM, Pawar SD, et al
   Phylogeography and gene pool analysis of highly pathogenic avian influenza H5N1 viruses reported in India from 2006 to 2021.
   Arch Virol. 2024;169:111.
   PubMed         Abstract available
   
2. YOUSFI FZE, Haroun AE, Nebhani C, Belayachi J, et al
   Prevalence of the protective OAS1 rs10774671-G allele against severe COVID-19 in Moroccans: implications for a North African Neanderthal connection.
   Arch Virol. 2024;169:109.
   PubMed         Abstract available
   
3. HAIDER SA, Jamal Z, Tahir F, Salman M, et al
   Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023.
   Arch Virol. 2024;169:106.
   PubMed         Abstract available
   
   
   Biochem Soc Trans
4. MARINUS T, Foster TL, Tych KM
   The application of single-molecule optical tweezers to study disease-related structural dynamics in RNA.
   Biochem Soc Trans. 2024;52:899-909.
   PubMed         Abstract available
   
   
   BMJ
5. 
   Seven days in medicine: 17-23 April 2024.
   BMJ. 2024;385:q924.
   PubMed        
   
6. LOOI MK
   Sixty seconds on . . . bird flu.
   BMJ. 2024;385:q951.
   PubMed        
   
7. KANG D
   The ever looming shadow of caregiving.
   BMJ. 2024;385:q726.
   PubMed        
   
8. LAUNER J
   John Launer: Doctors as activists.
   BMJ. 2024;385:q939.
   PubMed        
   
   
   J Exp Med
9. MACLEAN AJ, Bonifacio JPPL, Oram SL, Mohsen MO, et al
   Regulation of pulmonary plasma cell responses during secondary infection with influenza virus.
   J Exp Med. 2024;221:e20232014.
   PubMed         Abstract available
   
   
   JAMA
10. HARRIS E
    Antidepressant Prescriptions for Female Teens Surged After Pandemic.
    JAMA. 2024;331:1266.
    PubMed        
    
11. HARRIS E
    Deaths From Excessive Drinking Rose in the US During Pandemic.
    JAMA. 2024;331:1355.
    PubMed        
    
12. HARRIS E
    Meta-Analysis: “Limited” Benefits to Rapid Viral Tests in EDs.
    JAMA. 2024;331:1355.
    PubMed        
    
    
    Lancet
13. DEVI S
    Swedish NGOs are reeling after government cuts.
    Lancet. 2024;403:1527.
    PubMed        
    
    
    Minerva Pediatr (Torino)
14. MEMEO A, Priano D, Caldarini C, Trezza P, et al
    How the pandemic spread of COVID-19 affected children’s traumatology in Italy: changes of numbers, anatomical locations, and severity.
    Minerva Pediatr (Torino). 2024;76:167-172.
    PubMed         Abstract available
    
15. GARG D, Bhalla K, Nanda S, Gupta A, et al
    Vitamin D status in children with community acquired pneumonia and its association with severity: a hospital-based study.
    Minerva Pediatr (Torino). 2024;76:227-235.
    PubMed         Abstract available
    
16. LEE S, Erdem G, Yasuhara J
    Multisystem inflammatory syndrome in children associated with COVID-19: from pathophysiology to clinical management and outcomes.
    Minerva Pediatr (Torino). 2024;76:268-280.
    PubMed         Abstract available
    
17. PEROS TE, Besseling MR, VAN Zanten E, VAN Heerde M, et al
    Increase in pediatric intensive care mortality after the Coronavirus pandemic.
    Minerva Pediatr (Torino). 2023 Sep 21. doi: 10.23736/S2724-5276.23.07288.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
18. FRANKLIN D, Barbre K, Rowe TA, Reses HE, et al
    COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes – National Healthcare Safety Network, United States, October 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:339-344.
    PubMed         Abstract available
    
19. ZAMBRANO LD, Newhams MM, Simeone RM, Payne AB, et al
    Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents – United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:330-338.
    PubMed         Abstract available
    
20. PANAGIOTAKOPOULOS L, Godfrey M, Moulia DL, Link-Gelles R, et al
    Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged >/=65 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:377-381.
    PubMed         Abstract available
    
21. SMITH-JEFFCOAT SE, Mellis AM, Grijalva CG, Talbot HK, et al
    SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance – Respiratory Virus Transmission Network, November 2022-May 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:365-371.
    PubMed         Abstract available
    
    
    N Engl J Med
22. WANG Y, Hu H, Cao B
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply.
    N Engl J Med. 2024;390:1534-1535.
    PubMed        
    
23. SELVI-SABATER P, de la Rubia Orti JE, Urbieta-Sanz E
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1534.
    PubMed        
    
24. MOSER CB, Li JZ, Hughes MD
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1533-1534.
    PubMed        
    
    
    PLoS Comput Biol
25. BENISTON E, Skittrall JP
    Locations and structures of influenza A virus packaging-associated signals and other functional elements via an in silico pipeline for predicting constrained features in RNA viruses.
    PLoS Comput Biol. 2024;20:e1012009.
    PubMed         Abstract available
    
26. LISON A, Abbott S, Huisman J, Stadler T, et al
    Generative Bayesian modeling to nowcast the effective reproduction number from line list data with missing symptom onset dates.
    PLoS Comput Biol. 2024;20:e1012021.
    PubMed         Abstract available
    
    
    PLoS One
27. YAZDANI A, Mozaffarpur SA, Ebrahimi P, Shirafkan H, et al
    Comorbidities affecting re-admission and survival in COVID-19: Application of joint frailty model.
    PLoS One. 2024;19:e0301209.
    PubMed         Abstract available
    
28. TIAN J
    Rural household vulnerability and COVID-19: Evidence from India.
    PLoS One. 2024;19:e0301662.
    PubMed         Abstract available
    
29. CHAZE M, Meriade L, Rochette C, Bailly M, et al
    Relying on the French territorial offer of thermal spa therapies to build a care pathway for long COVID-19 patients.
    PLoS One. 2024;19:e0302392.
    PubMed         Abstract available
    
30. MESESAN-SCHMITZ L, Coman C, Stanciu C, Bucur V, et al
    Changes in parenting behavior in the time of COVID-19: A mixed method approach.
    PLoS One. 2024;19:e0302125.
    PubMed         Abstract available
    
31. HAMASHA MM, Alomari AJ, Bani-Irshid AH
    The effect of the COVID-19 pandemic crisis on the Jordanian higher education system.
    PLoS One. 2024;19:e0299531.
    PubMed         Abstract available
    
32. RAZAI MS, Mansour R, Ravindran P, Freeman S, et al
    Facilitators and barriers to vaccination uptake in pregnancy: A qualitative systematic review.
    PLoS One. 2024;19:e0298407.
    PubMed         Abstract available
    
33. FANG F, Clemens JD, Zhang ZF, Brewer TF, et al
    Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States.
    PLoS One. 2024;19:e0301830.
    PubMed         Abstract available
    
34. CHOUAIRI F, Jaffe E, Minhas AMK, Fudim M, et al
    Brief report: Effect of cardiac multi-morbidity on COVID hospitalization outcomes.
    PLoS One. 2024;19:e0301898.
    PubMed         Abstract available
    
35. SHAFIABADY N, Hadjinicolaou N, Hettikankanamage N, MohammadiSavadkoohi E, et al
    eXplainable Artificial Intelligence (XAI) for improving organisational regility.
    PLoS One. 2024;19:e0301429.
    PubMed         Abstract available
    
36. BEST LG, Erdei E, Haack K, Kent JW Jr, et al
    Genetic variant rs1205 is associated with COVID-19 outcomes: The Strong Heart Study and Strong Heart Family Study.
    PLoS One. 2024;19:e0302464.
    PubMed         Abstract available
    
37. WHITE A, Iverson G, Wright L, Fallon JT 3rd, et al
    Wastewater based epidemiology as a surveillance tool during the current COVID-19 pandemic on a college campus (East Carolina University) and its accuracy in predicting SARS-CoV-2 outbreaks in dormitories.
    PLoS One. 2024;19:e0289906.
    PubMed         Abstract available
    
38. ZHANG Q, Tiwari S, Wen J, Wang S, et al
    Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice.
    PLoS One. 2024;19:e0300524.
    PubMed         Abstract available
    
39. MILANTI A, Chan DNS, Choi KC, So WKW, et al
    eHealth literacy of migrant domestic workers in Hong Kong in the COVID-19 pandemic: A mixed methods study.
    PLoS One. 2024;19:e0296893.
    PubMed         Abstract available
    
40. SILVA JUNIOR DDN, de Sousa Mata AN, Silva de Medeiros GCB, Marques MV, et al
    Factors associated with mortality of elderly people due to COVID-19: Protocol for systematic review and meta-analysis.
    PLoS One. 2024;19:e0289576.
    PubMed         Abstract available
    
41. KHAMI MR, Karimi M, Folayan MO, Shamshiri AR, et al
    Patients’ knowledge about dental emergencies, COVID-19 transmission, and required preparations in dental settings.
    PLoS One. 2024;19:e0301460.
    PubMed         Abstract available
    
42. VIANNA LS, Goncalves AL, Souza JA
    Analysis of learning curves in predictive modeling using exponential curve fitting with an asymptotic approach.
    PLoS One. 2024;19:e0299811.
    PubMed         Abstract available
    
43. ZHU Y, Kiran S, Salman M, Sherwani S, et al
    From crisis to responsibility: The role of industry type, leadership style, and regulatory environment in shaping post-COVID-19 CSR initiative.
    PLoS One. 2024;19:e0292732.
    PubMed         Abstract available
    
44. ERVIN J, Fleitas Alfonzo L, Taouk Y, Maheen H, et al
    Unpaid caregiving and mental health during the COVID-19 pandemic-A systematic review of the quantitative literature.
    PLoS One. 2024;19:e0297097.
    PubMed         Abstract available
    
45. PARK SY, Lee R, Newton C, Han G, et al
    How are people coping with working from home during the COVID-19 pandemic?: Experiences from the Netherlands and South Korea.
    PLoS One. 2024;19:e0301351.
    PubMed         Abstract available
    
46. KASSA ZY, Scarf V, Turkmani S, Fox D, et al
    Impact of COVID-19 on antenatal care provision at public hospitals in the Sidama region, Ethiopia: A mixed methods study.
    PLoS One. 2024;19:e0301994.
    PubMed         Abstract available
    
47. RAZAFINDRAKOTO M, Roubaud F, Castilho MR, Pero V, et al
    Investigating the ‘Bolsonaro effect’ on the spread of the Covid-19 pandemic: An empirical analysis of observational data in Brazil.
    PLoS One. 2024;19:e0288894.
    PubMed         Abstract available
    
48. MARTINEZ-RAMOS MM, Vyas M, Majari P, Seligman TH, et al
    COVID anomaly in the correlation analysis of S&P 500 market states.
    PLoS One. 2024;19:e0301238.
    PubMed         Abstract available
    
49. BADE V, Schmitz H, Tawiah BB
    Regional variations in vaccination against COVID-19 in Germany.
    PLoS One. 2024;19:e0296976.
    PubMed         Abstract available
    
50. HONG SH, Jiang X, Kwon H
    Use of bio-information and communication technology shortens time to peak at a lower height of the epidemic curve: An alternative to flattening for countries with early COVID-19 outbreaks.
    PLoS One. 2024;19:e0301669.
    PubMed         Abstract available
    
51. HUSSAIN A, Hussain Z, Gogate M, Dashtipour K, et al
    Impact of the Covid-19 pandemic on audiology service delivery: Observational study of the role of social media in patient communication.
    PLoS One. 2024;19:e0288223.
    PubMed         Abstract available
    
52. MAJRASHI TA, El Hassab MA, Mahmoud SH, Mostafa A, et al
    In vitro biological evaluation and in silico insights into the antiviral activity of standardized olive leaves extract against SARS-CoV-2.
    PLoS One. 2024;19:e0301086.
    PubMed         Abstract available
    
53. COGILL S, Nallamshetty S, Fullenkamp N, Heberer K, et al
    Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning.
    PLoS One. 2024;19:e0290221.
    PubMed         Abstract available
    
54. WANG J, Hu L, Zhang T, Liu J, et al
    Prevalence and predictors of prenatal depression during the COVID-19 pandemic: A multistage observational study in Beijing, China.
    PLoS One. 2024;19:e0298314.
    PubMed         Abstract available
    
55. DLAMINI M, Msolo L, Ehi Ebomah K, Nontongana N, et al
    A systematic review on the incidence of influenza viruses in wastewater matrices: Implications for public health.
    PLoS One. 2024;19:e0291900.
    PubMed         Abstract available
    
56. MAGANA-AVILA GR, Moreno E, Plata C, Carbajal-Contreras H, et al
    Effect of SARS-CoV-2 S protein on the proteolytic cleavage of the epithelial Na+ channel ENaC.
    PLoS One. 2024;19:e0302436.
    PubMed         Abstract available
    
57. LEDON-LLANES L, Contreras-Yanez I, Guaracha-Basanez GA, Valverde-Hernandez SS, et al
    Sexual and reproductive health while living with rheumatoid arthritis: The impact of the disease stage on patient perspectives.
    PLoS One. 2024;19:e0302284.
    PubMed         Abstract available
    
58. SARVANDIAN S, Hosseinpour S, Hoseinynejad K, Davasaz Irani R, et al
    Mental health status in healthcare workers during COVID-19 pandemic: An online questionnaire study in the southwest Iran.
    PLoS One. 2024;19:e0298058.
    PubMed         Abstract available
    
    
    Vaccine
59. SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
    Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
    Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
60. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
61. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
62. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
63. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
64. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
65. GONG JD, Barnboym E, O’Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
66. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
    Virus Res
67. WANG Z, Sun W, Li D, Sun Y, et al
    A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice.
    Virus Res. 2024;345:199378.
    PubMed         Abstract available
    
68. KHAIRNAR K, Tomar SS
    COVID-19 genome surveillance: A geographical landscape and mutational mapping of SARS-CoV-2 variants in central India over two years.
    Virus Res. 2024;344:199365.
    PubMed         Abstract available
    
69. LUO L, Lv J
    An evolutionary theory on virus mutation in COVID-19.
    Virus Res. 2024;344:199358.
    PubMed         Abstract available
    
70. SCHAFER A, Gralinski LE, Leist SR, Hampton BK, et al
    Genetic loci regulate Sarbecovirus pathogenesis: A comparison across mice and humans.
    Virus Res. 2024;344:199357.
    PubMed         Abstract available
    
71. SCHMITZ T, Freuer D, Gosslau Y, Warm TD, et al
    Can inflammatory plasma proteins predict Long COVID or Fatigue severity after SARS-CoV-2 infection?
    Virus Res. 2024;344:199363.
    PubMed         Abstract available
    
72. KHEMIRI H, Mangone I, Gdoura M, Mefteh K, et al
    Dynamic of SARS-CoV-2 variants circulation in Tunisian pediatric population, during successive waves, from March 2020 to September 2022.
    Virus Res. 2024;344:199353.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 20 ’24)

1. ATRAMONT A, Martin GL, Singer M, Tajahmady A, et al
   One-Year Survival and Hospital-free Days in Critical Illness After Viral Pneumonia.
   Am J Respir Crit Care Med. 2024;209:1019-1022.
   PubMed        
   
   
   Ann Intern Med
2. WEITZ HH, Merli GJ
   Annals Consult Guys – COVID-19 and Surgery: A Postpandemic Update.
   Ann Intern Med. 2024;177:eW240001.
   PubMed        
   
3. ALHAMMADI A, Alshawaf R, Chavda S, Ramondino S, et al
   Infectious Diseases: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0679.
   PubMed         Abstract available
   
4. COSCHI CH, Dodbiba L, Guerry D
   Oncology: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0520.
   PubMed         Abstract available
   
5. ALHABOBI AAM, Almutairi AMS, Bohemid DASY, Sehgal AR, et al
   Nephrology: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0605.
   PubMed         Abstract available
   
   
   BMJ
6. COLLINS GS, Moons KGM, Dhiman P, Riley RD, et al
   TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.
   BMJ. 2024;385:e078378.
   PubMed         Abstract available
   
7. MAHASE E
   Covid-19: Charities question inquiry’s “refusal” to fully examine mental health impact.
   BMJ. 2024;385:q852.
   PubMed        
   
   
   Clin Infect Dis
8. 
   Correction to: Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients.
   Clin Infect Dis. 2024 Apr 15:ciae165. doi: 10.1093.
   PubMed        
   
   
   Infect Control Hosp Epidemiol
9. BUCHANAN MO, Sickbert-Bennett EE, Selimos A, Dean SM, et al
   Strategies to maintain an N95 respirator supply during a pandemic supply-chain shortage.
   Infect Control Hosp Epidemiol. 2024;45:688-689.
   PubMed        
   
   
   Int J Infect Dis
10. SLURINK IAL, van den Houdt SCM, Mertens G
    Who develops long COVID? Longitudinal pre-pandemic predictors of long COVID and symptom clusters in a representative Dutch population.
    Int J Infect Dis. 2024 Apr 10:107048. doi: 10.1016/j.ijid.2024.107048.
    PubMed         Abstract available
    
11. VERGORI A, Lepri AC, Chiuchiarelli M, Mazzotta V, et al
    Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era.
    Int J Infect Dis. 2024 Apr 11:107042. doi: 10.1016/j.ijid.2024.107042.
    PubMed         Abstract available
    
12. CHEN H, Yu L, Wang L, Zhang J, et al
    Demographic characteristics and risk factors for invasive fungal sinusitis in the context of COVID-19: A systematic review and meta-analysis.
    Int J Infect Dis. 2024 Apr 11:107054. doi: 10.1016/j.ijid.2024.107054.
    PubMed         Abstract available
    
13. LIEW YX, Ho AYL, Wong GC, Chung SJ, et al
    A retrospective study of intravenous pentamidine for PCP prophylaxis in adult patients with hematological malignancies – its utility during respiratory virus pandemics.
    Int J Infect Dis. 2024 Apr 12:107059. doi: 10.1016/j.ijid.2024.107059.
    PubMed         Abstract available
    
14. GRONING R, Walde J, Ahlm C, Forsell MN, et al
    Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: a retrospective cohort study.
    Int J Infect Dis. 2024 Apr 12:107046. doi: 10.1016/j.ijid.2024.107046.
    PubMed         Abstract available
    
15. GLASER N, Diexer S, Klee B, Purschke DO, et al
    The contribution of SARS-CoV-2 to the burden of acute respiratory infections in winter season 2022/2023: Results from the DigiHero study.
    Int J Infect Dis. 2024 Apr 15:107057. doi: 10.1016/j.ijid.2024.107057.
    PubMed         Abstract available
    
16. RICCIO MD, Caini S, Bonaccorsi G, Lorini C, et al
    Global analysis of respiratory viral circulation and timing of epidemics in the pre-COVID-19 and COVID-19 pandemic eras, based on data from the Global Influenza Surveillance and Response System (GISRS).
    Int J Infect Dis. 2024 Apr 16:107052. doi: 10.1016/j.ijid.2024.107052.
    PubMed         Abstract available
    
17. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Incidence of SARS-CoV-2 Seropositivity in Pediatric Healthcare Workers Prior to Widespread Vaccination: A Five-month Longitudinal Cohort Study.
    Int J Infect Dis. 2024 Apr 17:107064. doi: 10.1016/j.ijid.2024.107064.
    PubMed         Abstract available
    
    
    J Infect
18. CHUN JY, Jeong SJ, Kim S, Choi S, et al
    Performance of the Galactomannan Test for the Diagnosis of Invasive Pulmonary Aspergillosis using Non-invasive Proximal Airway Samples.
    J Infect. 2024 Apr 17:106159. doi: 10.1016/j.jinf.2024.106159.
    PubMed         Abstract available
    
    
    J Med Virol
19. MENG H, Wang Y, Zhai Y, Luo W, et al
    Unveiling the micronutrient-immunity puzzle in inactivated COVID-19 vaccination: A comprehensive analysis of circulating micronutrient levels and humoral responses in healthy adults.
    J Med Virol. 2024;96:e29611.
    PubMed         Abstract available
    
20. MAHLA RS, Dustin LB
    COVID-19 vaccination and autoimmunity: Do we need more evidence?
    J Med Virol. 2024;96:e29623.
    PubMed        
    
21. WEI M, Li S, Lu X, Hu K, et al
    Changing respiratory pathogens infection patterns after COVID-19 pandemic in Shanghai, China.
    J Med Virol. 2024;96:e29616.
    PubMed         Abstract available
    
22. OKITSU S, Khamrin P, Hikita T, Onda Y, et al
    Remarkable increase in the detection and molecular characterization of adenovirus F41 in children with acute gastroenteritis in Japan, 2017-2023.
    J Med Virol. 2024;96:e29615.
    PubMed         Abstract available
    
23. MATUSALI G, Vergori A, Cimini E, Mariotti D, et al
    Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
    J Med Virol. 2024;96:e29598.
    PubMed         Abstract available
    
24. CHEN IW, Weng HL, Lai YC, Hung KC, et al
    Incidence of fatigue 2 years after SARS-CoV-2 infection: An updated meta-analysis and subgroup analysis.
    J Med Virol. 2024;96:e29619.
    PubMed        
    
25. DESTREMAU M, Chaussade H, Hemar V, Beguet M, et al
    Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
    J Med Virol. 2024;96:e29603.
    PubMed         Abstract available
    
26. SUN Q, Gao J, An R, Wang M, et al
    Probing molecular pathways: Illuminating the connection between COVID-19 and Alzheimer’s disease through the endocannabinoid system dynamics.
    J Med Virol. 2024;96:e29590.
    PubMed         Abstract available
    
    
    J Travel Med
27. WARDLE J, Bhatia S, Cori A, Nouvellet P, et al
    Temporal variations in international air travel: implications for modelling the spread of infectious diseases.
    J Travel Med. 2024 Mar 17:taae062. doi: 10.1093.
    PubMed         Abstract available
    
    
    J Virol
28. HAN Y, Yuan Z, Yi Z
    Identification of a membrane-associated element (MAE) in the C-terminal region of SARS-CoV-2 nsp6 that is essential for viral replication.
    J Virol. 2024 Apr 19:e0034924. doi: 10.1128/jvi.00349.
    PubMed         Abstract available
    
29. PEREZ DR
    A devastating blow: personal reflections on Argentina’s scientific decline.
    J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
    PubMed         Abstract available
    
30. EBRIGHT RH, MacIntyre R, Dudley JP, Butler CD, et al
    Implementing governmental oversight of enhanced potential pandemic pathogen research.
    J Virol. 2024;98:e0023724.
    PubMed        
    
31. TAKADA K, Orba Y, Kida Y, Wu J, et al
    Genes involved in the limited spread of SARS-CoV-2 in the lower respiratory airways of hamsters may be associated with adaptive evolution.
    J Virol. 2024 Apr 16:e0178423. doi: 10.1128/jvi.01784.
    PubMed         Abstract available
    
32. WANG X, Qiu W, Hu G, Diao X, et al
    NS7a of SADS-CoV promotes viral infection via inducing apoptosis to suppress type III interferon production.
    J Virol. 2024 Apr 16:e0031724. doi: 10.1128/jvi.00317.
    PubMed         Abstract available
    
33. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
    Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
    PubMed         Abstract available
    
    
    Lancet Infect Dis
34. 
    Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    PubMed         Abstract available
    
35. 
    Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Apr 15:S1473-3099(24)00176.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
36. FRANKLIN D, Barbre K, Rowe TA, Reses HE, et al
    COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes – National Healthcare Safety Network, United States, October 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:339-344.
    PubMed         Abstract available
    
37. ZAMBRANO LD, Newhams MM, Simeone RM, Payne AB, et al
    Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents – United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:330-338.
    PubMed         Abstract available
    
    
    Nature
38. DOLGIN E
    mRNA drug offers hope for treating a devastating childhood disease.
    Nature. 2024;628:248.
    PubMed        
    
39. KOZLOV M
    US COVID-origins hearing puts scientific journals in the hot seat.
    Nature. 2024 Apr 16. doi: 10.1038/d41586-024-01129.
    PubMed        
    
40. LADYZHETS B
    What toilets can reveal about COVID, cancer and other health threats.
    Nature. 2024;628:492-494.
    PubMed        
    
    
    Science
41. COUZIN-FRANKEL J
    Lessons in persistence.
    Science. 2024;384:150-154.
    PubMed         Abstract available

#Influenza and #COVID19 Research #References (by Amedeo.com, April 20 ’24)

1. KOW CS, Ramachandram DS, Hasan SS, Thiruchelvam K, et al
   Navigating the Shadows: COVID-19’s Lingering Threat – Pulmonary Fibrosis.
   Am J Med. 2024;137:e81.
   PubMed        
   
   
   Ann Intern Med
2. WEITZ HH, Merli GJ
   Annals Consult Guys – COVID-19 and Surgery: A Postpandemic Update.
   Ann Intern Med. 2024;177:eW240001.
   PubMed        
   
3. GOTUR D, Mylonakis E
   In adults with post-COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 mo.
   Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0018.
   PubMed         Abstract available
   
   
   Antiviral Res
4. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
   Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
   Antiviral Res. 2024;225:105874.
   PubMed         Abstract available
   
5. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
   New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
   Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
   PubMed         Abstract available
   
6. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
   Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
   Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
   PubMed         Abstract available
   
7. MOON C, Porges E, Roberts A, Bacon J, et al
   A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
   Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
   PubMed         Abstract available
   
8. WANG W, Wang S, Meng X, Zhao Y, et al
   A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
   Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
   PubMed         Abstract available
   
9. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
   Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
   Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
   PubMed         Abstract available
   
10. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    PubMed         Abstract available
    
    
    Arch Virol
11. BEDAIR NM, Sakr MA, Mourad A, Eissa N, et al
    Molecular characterization of the whole genome of H9N2 avian influenza virus isolated from Egyptian poultry farms.
    Arch Virol. 2024;169:99.
    PubMed         Abstract available
    
    
    Biochem Biophys Res Commun
12. KALASHNYK O, Lykhmus O, Sullivan R, Komisarenko S, et al
    Agonists or positive allosteric modulators of alpha7 nicotinic acetylcholine receptor prevent interaction of SARS-Cov-2 receptor-binding domain with astrocytoma cells.
    Biochem Biophys Res Commun. 2024;709:149825.
    PubMed         Abstract available
    
    
    BMC Pediatr
13. JIANG J, Shen Z, Cao J
    Seizures in febrile children with SARS-CoV-2 infection: clinical features, short-term follow-up.
    BMC Pediatr. 2024;24:257.
    PubMed         Abstract available
    
14. LIN F, Jiang DJ, Zhang S, Yang Z, et al
    Critically ill children with SARS-COV-2 Omicron infection at a national children medical center, Guangdong, China.
    BMC Pediatr. 2024;24:254.
    PubMed         Abstract available
    
    
    BMJ
15. MAHASE E
    Covid-19: Charities question inquiry’s “refusal” to fully examine mental health impact.
    BMJ. 2024;385:q852.
    PubMed        
    
    
    Cell
16. WAYNE CJ, Blakney AK
    Self-amplifying RNA COVID-19 vaccine.
    Cell. 2024;187:1822-1822.
    PubMed         Abstract available
    
    
    Drug Saf
17. CAPLANUSI I, Szmigiel A, van der Elst M, Schougaard Christiansen ML, et al
    The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
    Drug Saf. 2024;47:405-418.
    PubMed         Abstract available
    
    
    J Infect Dis
18. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
    Hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural infection or vaccination alone.
    J Infect Dis. 2024 Jan 29:jiae046. doi: 10.1093.
    PubMed        
    
19. HUH K, Kang M, Kim YE, Choi Y, et al
    Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients.
    J Infect Dis. 2023 Dec 14:jiad501. doi: 10.1093.
    PubMed         Abstract available
    
20. TUTTLE DJ, Castanha PMS, Nasser A, Wilkins MS, et al
    SARS-CoV-2 mRNA vaccines induce greater complement activation and decreased viremia and Nef antibodies in men with HIV-1.
    J Infect Dis. 2023 Nov 30:jiad544. doi: 10.1093.
    PubMed         Abstract available
    
21. MORI M, Doi T, Murata M, Moriyama Y, et al
    Impact of nutritional status on antibody titer after booster mRNA COVID-19 vaccine among elderly adults in Japan.
    J Infect Dis. 2023 Nov 14:jiad495. doi: 10.1093.
    PubMed         Abstract available
    
22. ZAMA D, Zanaroli A, Corbelli A, Lo Vecchio A, et al
    SARS-CoV-2 Infection in the Pediatric Oncology Population: The Definitive Comprehensive Report of the Infectious Diseases Working Group of AIEOP.
    J Infect Dis. 2024;229:1050-1058.
    PubMed         Abstract available
    
23. GUILBAUD R, Franco Yusti AM, Leducq V, Zafilaza K, et al
    Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.
    J Infect Dis. 2024;229:1041-1049.
    PubMed         Abstract available
    
24. ASAMOAH-BOAHENG M, Grunau B, Karim ME, Kirkham TL, et al
    The association of post-COVID-related symptoms and preceding SARS-CoV-2 infection among fully vaccinated paramedics in Canada.
    J Infect Dis. 2023 Oct 31:jiad475. doi: 10.1093.
    PubMed         Abstract available
    
25. SIMOES EAF, Botteman M, Chirikov V
    Epidemiology of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection in Japanese Children, 2011-2017.
    J Infect Dis. 2024;229:1112-1122.
    PubMed         Abstract available
    
26. SARIOL A, Vickers MA, Christensen SM, Weiskopf D, et al
    Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients.
    J Infect Dis. 2023 Aug 25:jiad366. doi: 10.1093.
    PubMed         Abstract available
    
    
    J Virol
27. BOUGON J, Kadijk E, Gallot-Lavallee L, Curtis BA, et al
    Influenza A virus NS1 effector domain is required for PA-X-mediated host shutoff in infected cells.
    J Virol. 2024 Apr 17:e0190123. doi: 10.1128/jvi.01901.
    PubMed         Abstract available
    
28. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
    The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
    J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
    PubMed         Abstract available
    
29. BABOT M, Boulard Y, Agouda S, Pieri L, et al
    Oligomeric assembly of the C-terminal and transmembrane region of SARS-CoV-2 nsp3.
    J Virol. 2024 Mar 14:e0157523. doi: 10.1128/jvi.01575.
    PubMed         Abstract available
    
30. ZHENG T, Shen B, Bai Y, Li E, et al
    The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association.
    J Virol. 2024 Mar 6:e0156523. doi: 10.1128/jvi.01565.
    PubMed         Abstract available
    
    
    JAMA
31. HARRIS E
    COVID-19 Associated With Higher Risk of Autoimmune Diseases.
    JAMA. 2024 Mar 22. doi: 10.1001/jama.2024.2092.
    PubMed        
    
32. HARRIS E
    COVID-19 Infection Tied to Slight Cognitive Deficits.
    JAMA. 2024 Mar 22. doi: 10.1001/jama.2024.2087.
    PubMed        
    
    
    Lancet
33. WENHAM C, Stout L
    A legal mapping of 48 WHO member states’ inclusion of public health emergency of international concern, pandemic, and health emergency terminology within national emergency legislation in responding to health emergencies.
    Lancet. 2024 Mar 22:S0140-6736(24)00156-9. doi: 10.1016/S0140-6736(24)00156.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
34. LIKO J, Cieslak PR
    Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine – Oregon, June 2021-December 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:317-320.
    PubMed         Abstract available
    
35. DOSHI RH, Nsasiirwe S, Dahlke M, Atagbaza A, et al
    COVID-19 Vaccination Coverage – World Health Organization African Region, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:307-311.
    PubMed         Abstract available
    
    
    PLoS One
36. WEISSFLOG M, Kim S, Rajack N, Kolla NJ, et al
    The impact of the COVID-19 pandemic on the use of restraint and seclusion interventions in Ontario emergency departments: A population-based study.
    PLoS One. 2024;19:e0302164.
    PubMed         Abstract available
    
37. ANDRONESCU LR, Richard SA, Scher AI, Lindholm DA, et al
    SARS-CoV-2 infection is associated with self-reported post-acute neuropsychological symptoms within six months of follow-up.
    PLoS One. 2024;19:e0297481.
    PubMed         Abstract available
    
38. HOTEIT R, Bou-Hamad I, Hijazi S, Ayna D, et al
    A cross-sectional study of university students’ mental health and lifestyle practices amidst the COVID-19 pandemic.
    PLoS One. 2024;19:e0302265.
    PubMed         Abstract available
    
39. KYAKUWA N, Kimbugwe G, Nakanjako F, Kalute H, et al
    High uptake of COVID-19 vaccines among healthcare workers in urban Uganda.
    PLoS One. 2024;19:e0277072.
    PubMed         Abstract available
    
40. HOTH KF, Ten Eyck P, Harland KK, Krishnadasan A, et al
    Availability and use of institutional support programs for emergency department healthcare personnel during the COVID-19 pandemic.
    PLoS One. 2024;19:e0298807.
    PubMed         Abstract available
    
41. PSZCZOLKOWSKA D, Bojarczuk S, Duszczyk M, Matuszczyk K, et al
    Did Covid-19 make things worse? The pandemic as a push factor stimulating the emigration intentions of junior doctors from Poland: A mixed methods study.
    PLoS One. 2024;19:e0301757.
    PubMed         Abstract available
    
42. LIN L, Demirhan H, P Johnstone-Robertson S, Lal R, et al
    Assessing the impact of Australia’s mass vaccination campaigns over the Delta and Omicron outbreaks.
    PLoS One. 2024;19:e0299844.
    PubMed         Abstract available
    
43. MOHEBBI A, Eskandarzadeh M, Zangi H, Fatehi M, et al
    In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease.
    PLoS One. 2024;19:e0298201.
    PubMed         Abstract available
    
44. GOODKIND JR, Van Horn ML, Hess JM, Lardier D, et al
    Protocol of the study: Multilevel community-based mental health intervention to address structural inequities and adverse disparate consequences of COVID-19 pandemic on Latinx Immigrants and African refugees.
    PLoS One. 2024;19:e0298369.
    PubMed         Abstract available
    
45. PAULOWSKI L, Filip R, Jankovic Makek M, Guglielmetti L, et al
    Impact of the COVID-19 pandemic on the real-world diagnostic infrastructure for tuberculosis-An ESGMYC collaborative study.
    PLoS One. 2024;19:e0291404.
    PubMed         Abstract available
    
46. KARAHAN D, Bolayir HA, Bolayir A, Demir B, et al
    Can serum interleukin 34 levels be used as an indicator for the prediction and prognosis of COVID-19?
    PLoS One. 2024;19:e0302002.
    PubMed         Abstract available
    
47. SALAMANCA-BUENTELLO F, Katz R, Silva DS, Upshur REG, et al
    Research ethics review during the COVID-19 pandemic: An international study.
    PLoS One. 2024;19:e0292512.
    PubMed         Abstract available
    
48. LIM SH, Lim YC, Zaki RA, Johari BM, et al
    Prevalence and predictors of post-acute COVID syndrome among infected healthcare workers at University Malaya Medical Centre.
    PLoS One. 2024;19:e0298376.
    PubMed         Abstract available
    
49. ABUHAMMAD S, Al-Natour A, Abu Al-Rub S, Hamaideh S, et al
    Intimate partner violence and quality of life among mothers in Jordan during COVID-19 era.
    PLoS One. 2024;19:e0298669.
    PubMed         Abstract available
    
50. CHOI Y
    Exploring the impact of pandemic fear on visitation to park attractions in urban city: A case study in Seoul, South Korea.
    PLoS One. 2024;19:e0301869.
    PubMed         Abstract available
    
51. JIANG J, Wang S, Li Y, Wang Y, et al
    Has-miR-199a-3p/RELA/SCD inhibits immune checkpoints in AMD and promotes macrophage-mediated inflammation and pathological angiogenesis through lipid metabolism pathway: A computational analysis.
    PLoS One. 2024;19:e0297849.
    PubMed         Abstract available
    
52. WIENER RC, Lundstrom EW
    Assessing the COVID-19 pandemic’s impact on pediatric baseball and basketball-related craniofacial and neck injuries treated in United States emergency departments, 2003-2022.
    PLoS One. 2024;19:e0302232.
    PubMed         Abstract available
    
53. JOSE R, Wang W, Sherman G, Rosenthal RN, et al
    Tapping into alcohol use during COVID: Drinking correlates among bartenders and servers.
    PLoS One. 2024;19:e0300932.
    PubMed         Abstract available
    
54. CHISTY ZA, Li DD, Haile M, Houston H, et al
    Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents-Georgia, October 2020-July 2022.
    PLoS One. 2024;19:e0301367.
    PubMed         Abstract available
    
55. WANG B, Waris M, Adamiak K, Adnan M, et al
    The effects of the COVID-19 pandemic period on stock market return and volatility. Evidence from the Pakistan Stock Exchange.
    PLoS One. 2024;19:e0295853.
    PubMed         Abstract available
    
56. MAYOR E, Lieb R
    Dispositional factors in the explanation of symptoms of depression, anxiety, health anxiety and COVID-19 Phobia.
    PLoS One. 2024;19:e0299593.
    PubMed         Abstract available
    
57. MOON MH, Choi MH
    Association between household income and mental health among adults during the COVID-19 pandemic in Korea: Insights from a community health survey.
    PLoS One. 2024;19:e0289230.
    PubMed         Abstract available
    
58. ZHANG F, Zhang J, Li M, Jin Z, et al
    Assessing the impact of different contact patterns on disease transmission: Taking COVID-19 as a case.
    PLoS One. 2024;19:e0300884.
    PubMed         Abstract available
    
59. MILLEST A, Saeed S, Symons C, Carter H, et al
    Effect of face-covering use on adherence to other COVID-19 protective behaviours: A systematic review.
    PLoS One. 2024;19:e0284629.
    PubMed         Abstract available
    
60. ZHILKOVA A, Alsabahi L, Olson D, Maru D, et al
    Hospital segregation, critical care strain, and inpatient mortality during the COVID-19 pandemic in New York City.
    PLoS One. 2024;19:e0301481.
    PubMed         Abstract available
    
61. RENEER ZB, Bergeron HC, Reynolds S, Thornhill-Wadolowski E, et al
    mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge.
    PLoS One. 2024;19:e0297833.
    PubMed         Abstract available
    
62. ITO MI, Honma Y, Ohnishi T, Watanabe T, et al
    Exogenous and endogenous factors affecting stock market transactions: A Hawkes process analysis of the Tokyo Stock Exchange during the COVID-19 pandemic.
    PLoS One. 2024;19:e0301462.
    PubMed         Abstract available
    
63. SANVEE-BLEBO LM, Adewuyi PA, Whesseh FK, Babalola OJ, et al
    COVID-19 vaccine hesitancy among adults in Liberia, April-May 2021.
    PLoS One. 2024;19:e0297089.
    PubMed         Abstract available
    
64. JOHNSTON DB, Coleman HG, Colvin D, Lawther S, et al
    Impact of COVID-19 on acute appendicitis presentation, management and pathology findings in adult and paediatric populations.
    PLoS One. 2024;19:e0300357.
    PubMed         Abstract available
    
65. CURTIS MG, Wieling E, Bryant C, Campbell RD, et al
    Systemic effects of the COVID pandemic on rural black American men’s interpersonal relationships: A phenomenological examination.
    PLoS One. 2024;19:e0297876.
    PubMed         Abstract available
    
66. KE GN, Gow A, Wong RMM, Raman S, et al
    Perceptions of risk and coping strategies during the COVID-19 pandemic among women and older adults.
    PLoS One. 2024;19:e0301009.
    PubMed         Abstract available
    
67. LOWHORN RJ, Chowdhury M, Kimitei S, Haskin S, et al
    Comorbidities and their association with COVID-19 mortality in Mexico between January 2020 and August 2021.
    PLoS One. 2024;19:e0296895.
    PubMed         Abstract available
    
68. PAWLAK K, Malak-Rawlikowska A, Hamulczuk M, Skrzypczyk M, et al
    Has food security in the EU countries worsened during the COVID-19 pandemic? Analysis of physical and economic access to food.
    PLoS One. 2024;19:e0302072.
    PubMed         Abstract available
    
69. ZAID SNA, Abdul Kadir A, Mohd Noor N, Ahmad B, et al
    Translation and trans-cultural adaptation to the Malay version of the COVID-19 vaccine hesitancy questionnaire among healthcare workers in Malaysia.
    PLoS One. 2024;19:e0302237.
    PubMed         Abstract available
    
70. LU A, Armstrong M, Alexander R, Vest E, et al
    Trends in pediatric prescription-opioid overdoses in U.S. emergency departments from 2008-2020: An epidemiologic study of pediatric opioid overdose ED visits.
    PLoS One. 2024;19:e0299163.
    PubMed         Abstract available
    
71. PARMAR J, L’Heureux T, Lobchuk M, Penner J, et al
    Double-duty caregivers enduring COVID-19 pandemic to endemic: “It’s just wearing me down”.
    PLoS One. 2024;19:e0298584.
    PubMed         Abstract available
    
72. ZHANG Y, Sui X, Zhang S
    Exploring spatio-temporal impact of COVID-19 on citywide taxi demand: A case study of New York City.
    PLoS One. 2024;19:e0299093.
    PubMed         Abstract available
    
73. VITORINO C, Canavarro MC, Carona C
    Six-month psychopathological symptom trajectories following the COVID-19 outbreak: Contrasting mental health outcomes between nurses and the general population.
    PLoS One. 2024;19:e0301527.
    PubMed         Abstract available
    
74. LERDSAMRAN H, Anusorntanawat R, Sangsiriwut K, Sawadpongpan S, et al
    Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients.
    PLoS One. 2024;19:e0298033.
    PubMed         Abstract available
    
75. TAN H, Liu J, Zhang Y
    Effects of COVID-19 vaccine safety framing on parental reactions.
    PLoS One. 2024;19:e0302233.
    PubMed         Abstract available
    
    
    Proc Natl Acad Sci U S A
76. FREEDMAN AS, Sheen JK, Tsai S, Yao J, et al
    Inferring COVID-19 testing and vaccination behavior from New Jersey testing data.
    Proc Natl Acad Sci U S A. 2024;121:e2314357121.
    PubMed         Abstract available
    
77. JOHANNESEN N, Tang-Andersen Martinello A, Meyer BB, Vestergaard ET, et al
    Substantial transmission of SARS-CoV-2 through casual contact in retail stores: Evidence from matched administrative microdata on card payments and testing.
    Proc Natl Acad Sci U S A. 2024;121:e2317589121.
    PubMed         Abstract available
    
    
    Vaccine
78. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
79. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
80. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
81. MARTINEZ JL, Lemus N, Lai TY, Mishra M, et al
    The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
    Vaccine. 2024 Apr 15:S0264-410X(24)00451-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
82. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
83. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
84. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
85. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
    Virus Res
86. LIU D, Leung KY, Lam HY, Zhang R, et al
    Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.
    Virus Res. 2024;345:199371.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 13 ’24)

1. RADCLIFFE C, Kotton CN
   En Garde or On Board? Travel Medicine for Immunocompromised Patients in the COVID-19 Era.
   Ann Intern Med. 2024 Apr 9. doi: 10.7326/M24-0256.
   PubMed        
   
   
   Antiviral Res
2. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
   Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
   Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
   PubMed         Abstract available
   
   
   Clin Infect Dis
3. MCAULEY JB
   COVID at the Whiteriver Indian Hospital.
   Clin Infect Dis. 2024;78:815-817.
   PubMed        
   
4. ZAWADZKA S
   Family Ties and COVID Lies.
   Clin Infect Dis. 2024;78:813-814.
   PubMed        
   
5. TIPPETT A, Ess G, Hussaini L, Reese O, et al
   Influenza Vaccine Effectiveness Pre-pandemic among Adults Hospitalized with Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and Older Adults.
   Clin Infect Dis. 2023 Nov 8:ciad679. doi: 10.1093.
   PubMed         Abstract available
   
6. VAN DER VAART TW, Prins JM, Goorhuis A, Lemkes BA, et al
   The utility of risk factors to define complicated Staphylococcus aureus bacteremia in a setting with low MRSA prevalence.
   Clin Infect Dis. 2023 Dec 29:ciad784. doi: 10.1093.
   PubMed         Abstract available
   
7. SHERMAN A, Tuan J, Cantos VD, Adeyiga O, et al
   COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
   Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093.
   PubMed         Abstract available
   
8. PETROS BA, Milliren CE, Sabeti PC, Ozonoff A, et al
   Increased Pediatric Respiratory Syncytial Virus Case Counts Following the Emergence of Severe Acute Respiratory Syndrome Coronavirus 2 Can Be Attributed to Changes in Testing.
   Clin Infect Dis. 2024 Apr 11:ciae140. doi: 10.1093.
   PubMed         Abstract available
   
9. RUBIS AB, Cole M, Tondella ML, Pawloski LC, et al
   Assessing the Impact of the 2020 Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis Cases.
   Clin Infect Dis. 2024 Apr 12:ciae207. doi: 10.1093.
   PubMed         Abstract available
   
   
   Int J Infect Dis
10. MARKUSSEN DL, Kommedal O, Knoop ST, Ebbesen MH, et al
    Microbial aetiology of community-acquired pneumonia in hospitalized adults: a prospective study utilising comprehensive molecular testing.
    Int J Infect Dis. 2024 Apr 4:107019. doi: 10.1016/j.ijid.2024.107019.
    PubMed         Abstract available
    
11. TAMURA K, Shimbashi R, Kasamatsu A, Chang B, et al
    Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan.
    Int J Infect Dis. 2024 Apr 5:107024. doi: 10.1016/j.ijid.2024.107024.
    PubMed         Abstract available
    
12. FAVRESSE J, Gillot C, Cabo J, David C, et al
    Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster.
    Int J Infect Dis. 2024 Apr 5:107028. doi: 10.1016/j.ijid.2024.107028.
    PubMed         Abstract available
    
13. YU J, Zhang K, Chen T, Lin R, et al
    Temporal patterns of organ dysfunction in COVID-19 patients hospitalized in the intensive care unit: A group-based multitrajectory modelling analysis.
    Int J Infect Dis. 2024 Apr 9:107045. doi: 10.1016/j.ijid.2024.107045.
    PubMed         Abstract available
    
    
    J Infect
14. PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al
    Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance.
    J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153.
    PubMed         Abstract available
    
    
    J Med Virol
15. ARUNAN B, Talukdar D, Swain S, Varadarajan A, et al
    Metagenomic insights into fungal community composition of the nasopharyngeal region of COVID-19 associated mucormycosis patients from India.
    J Med Virol. 2024;96:e29601.
    PubMed         Abstract available
    
16. LI Y, Yu J, Wang Y, Yi J, et al
    Cocirculation and coinfection of multiple respiratory viruses during autumn and winter seasons of 2023 in Beijing, China: A retrospective study.
    J Med Virol. 2024;96:e29602.
    PubMed         Abstract available
    
17. PARK D, Kim SM, Jang H, Kim K, et al
    Differential beta-coronavirus infection dynamics in human bronchial epithelial organoids.
    J Med Virol. 2024;96:e29600.
    PubMed         Abstract available
    
18. SVIERCZ F, Jarmoluk P, Godoy Coto J, Cevallos C, et al
    The abortive SARS-CoV-2 infection of osteoclast precursors promotes their differentiation into osteoclasts.
    J Med Virol. 2024;96:e29597.
    PubMed         Abstract available
    
19. RAI P, Marano JM, Kang L, Coutermarsh-Ott S, et al
    Obesity fosters severe disease outcomes in a mouse model of coronavirus infection associated with transcriptomic abnormalities.
    J Med Virol. 2024;96:e29587.
    PubMed         Abstract available
    
20. KURYLOWICZ A, Babicki M, Wasowski M, Jankowski P, et al
    Triglicerydes/high-density lipoprotein ratio as a risk factor of post-Covid-19 sinus tachycardia: A retrospective study.
    J Med Virol. 2024;96:e29586.
    PubMed         Abstract available
    
21. YE G, Tang Y, Yang Q, Zhang C, et al
    A peptide derived from SARS-CoV-2 nucleocapsid protein with broad-spectrum anti-coronavirus activity.
    J Med Virol. 2024;96:e29492.
    PubMed        
    
    
    J Travel Med
22. CHEMAITELLY H, Coyle P, Kacem MAB, Ayoub HH, et al
    Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant.
    J Travel Med. 2024 Apr 9:taae053. doi: 10.1093.
    PubMed         Abstract available
    
    
    J Virol
23. BOON ACM, Bricker TL, Fritch EJ, Leist SR, et al
    Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
    J Virol. 2024 Apr 9:e0190323. doi: 10.1128/jvi.01903.
    PubMed         Abstract available
    
24. ZHOU J, Sun P, Wang Y, Qiu R, et al
    Deep profiling of potential substrate atlas of porcine epidemic diarrhea virus 3C-like protease.
    J Virol. 2024 Apr 9:e0025324. doi: 10.1128/jvi.00253.
    PubMed         Abstract available
    
25. YANG R, Han P, Han P, Li D, et al
    Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.
    J Virol. 2024 Apr 9:e0045124. doi: 10.1128/jvi.00451.
    PubMed         Abstract available
    
    
    JAMA
26. HARRIS E
    COVID-19 Vaccination Linked With Lower Risk of Cardiac Problems.
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.5152.
    PubMed        
    
27. DAWOOD FS, Payne AB, McMorrow ML
    Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus.
    JAMA. 2024 Apr 11. doi: 10.1001/jama.2024.5859.
    PubMed        
    
    
    Lancet
28. 
    Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367.
    PubMed         Abstract available
    
29. GU X, Huang L, Zhang H, Cao B, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan – Authors’ reply.
    Lancet. 2024;403:1336-1337.
    PubMed        
    
30. SORAAS A, Brunvoll SH, Nygaard AB, Dahl JA, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan.
    Lancet. 2024;403:1336.
    PubMed        
    
31. HASHIM Z, Nath A, Tripathy NK
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337-1338.
    PubMed        
    
32. MCEVOY N, Lowry J, O’Dowd A, Curley GF, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337.
    PubMed        
    
33. HSU NC, Tokuda Y
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338.
    PubMed        
    
34. NARASARAJU T, Ravi Y, Jonsson CB, Chow VTK, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338-1339.
    PubMed        
    
35. BHUSAL S, Adhikari S
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1339.
    PubMed        
    
36. PETO L, Basnyat B, Horby P
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial – Authors’ reply.
    Lancet. 2024;403:1339-1340.
    PubMed        
    
37. ZUMLA A, Peiris M, Memish ZA, Perlman S, et al
    Anticipating a MERS-like coronavirus as a potential pandemic threat.
    Lancet. 2024 Apr 8:S0140-6736(24)00641-X. doi: 10.1016/S0140-6736(24)00641.
    PubMed        
    
    
    Lancet Infect Dis
38. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
39. DOSHI RH, Nsasiirwe S, Dahlke M, Atagbaza A, et al
    COVID-19 Vaccination Coverage – World Health Organization African Region, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:307-311.
    PubMed         Abstract available
    
40. LIKO J, Cieslak PR
    Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine – Oregon, June 2021-December 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:317-320.
    PubMed         Abstract available
    
    
    N Engl J Med
41. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
    Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    N Engl J Med. 2024;390:1186-1195.
    PubMed         Abstract available
    
42. GANDHI RT, Hirsch M
    Treating Acute Covid-19 – Final Chapters Still Unwritten.
    N Engl J Med. 2024;390:1234-1236.
    PubMed        
    
    
    Zhonghua Jie He He Hu Xi Za Zhi
43. SUN ZZ, Sun GF, Zhuang R, Zhu LQ, et al
    [Best evidence summary for awake prone positioning in treating hypoxemic due to COVID-19 infection].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:313-318.
    PubMed         Abstract available

#Influenza and #COVID19 Research #References (by Amedeo.com, April 13 ’24)

1. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
   Influenza C virus susceptibility to antivirals with different mechanisms of action.
   Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
   PubMed         Abstract available
   
   
   Arch Virol
2. KUTKAT O, Gomaa M, Aboulhoda BE, Moatasim Y, et al
   Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.
   Arch Virol. 2024;169:95.
   PubMed         Abstract available
   
   
   BMJ
3. LOOI MK
   Bird flu: Person with rare strain in US sparks alarm about cow transmission.
   BMJ. 2024;385:q797.
   PubMed        
   
   
   Epidemiol Infect
4. LOZANO D, Dohoo C, Elfstrom D, Carswell K, et al
   COVID-19 outbreak at a residential apartment building in Northern Ontario, Canada.
   Epidemiol Infect. 2024;152:e53.
   PubMed         Abstract available
   
5. TSANG TK, Du RQR, Fang VJ, Lau EHY, et al
   Decreased risk of non-influenza respiratory infection after influenza B virus infection in children.
   Epidemiol Infect. 2024 Apr 8:1-21. doi: 10.1017/S0950268824000542.
   PubMed        
   
6. NESTERUK I
   Should we ignore SARS-CoV-2 disease?
   Epidemiol Infect. 2024;152:e57.
   PubMed         Abstract available
   
   
   J Clin Microbiol
7. PARK SY, Faraci G, Ward P, Lee HY, et al
   Utilizing cost-effective portable equipment to enhance COVID-19 variant tracking both on-site and at a large scale.
   J Clin Microbiol. 2024;62:e0155823.
   PubMed         Abstract available
   
   
   J Exp Med
8. WU TT, Travaglini KJ, Rustagi A, Xu D, et al
   Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung.
   J Exp Med. 2024;221:e20232192.
   PubMed         Abstract available
   
   
   J Virol
9. BU H, Zhang S, Li P, Liu Z, et al
   Secreted phospholipase PLA2G2E contributes to regulation of T cell immune response against influenza virus infection.
   J Virol. 2024 Apr 9:e0019824. doi: 10.1128/jvi.00198.
   PubMed         Abstract available
   
   
   J Virol Methods
10. SUZUKI R, Kamiyama A, Ito H, Kawashiro K, et al
    The development of a rapid, high-throughput neutralization assay using a SARS-CoV-2 reporter.
    J Virol Methods. 2024;326:114894.
    PubMed         Abstract available
    
11. FERNANDEZ-SANCHEZ F, Martin-Bautista E, Rivas-Ruiz F, Wu W, et al
    Evaluation of the EasyNAT SARS-CoV-2 assay PCR test for the diagnosis of SARS-CoV-2 infection.
    J Virol Methods. 2024;326:114908.
    PubMed         Abstract available
    
12. BOESELT T, Terhorst P, Kroenig J, Nell C, et al
    Specific molecular peak analysis by ion mobility spectrometry of volatile organic compounds in urine of COVID-19 patients: A novel diagnostic approach.
    J Virol Methods. 2024;326:114910.
    PubMed         Abstract available
    
13. KATSUNO T, Kimura M, Terada-Hirashima J, Kazuyama Y, et al
    Diagnostic accuracy of direct reverse transcription-polymerase chain reaction using guanidine-based and guanidine-free inactivators for SARS-CoV-2 detection in saliva samples.
    J Virol Methods. 2024;326:114909.
    PubMed         Abstract available
    
14. LEE SS, Kim AL, Park JH, Lee DH, et al
    Optimization of duplex digital PCR for the measurement of SARS-CoV-2 RNA.
    J Virol Methods. 2024;326:114911.
    PubMed         Abstract available
    
15. BANG LL, Tornby DR, Pham STD, Assing K, et al
    Culturing of SARS-CoV-2 from patient samples: Protocol for optimal virus recovery and assessment of infectious viral load.
    J Virol Methods. 2024;326:114912.
    PubMed         Abstract available
    
    
    JAMA
16. NIELSEN FM, Klitgaard TL, Siegemund M, Laake JH, et al
    Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial.
    JAMA. 2024 Mar 19:e242934. doi: 10.1001/jama.2024.2934.
    PubMed         Abstract available
    
17. SCHWARTZSTEIN RM
    Oxygen Supplementation in COVID-19-How Much Is Enough?
    JAMA. 2024 Mar 19. doi: 10.1001/jama.2024.2935.
    PubMed        
    
    
    Lancet
18. NARASARAJU T, Ravi Y, Jonsson CB, Chow VTK, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338-1339.
    PubMed        
    
19. SORAAS A, Brunvoll SH, Nygaard AB, Dahl JA, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan.
    Lancet. 2024;403:1336.
    PubMed        
    
20. PETO L, Basnyat B, Horby P
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial – Authors’ reply.
    Lancet. 2024;403:1339-1340.
    PubMed        
    
21. HSU NC, Tokuda Y
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338.
    PubMed        
    
22. GU X, Huang L, Zhang H, Cao B, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan – Authors’ reply.
    Lancet. 2024;403:1336-1337.
    PubMed        
    
23. BHUSAL S, Adhikari S
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1339.
    PubMed        
    
24. MCEVOY N, Lowry J, O’Dowd A, Curley GF, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337.
    PubMed        
    
25. HASHIM Z, Nath A, Tripathy NK
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337-1338.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
26. EL KALACH R, Jones-Jack N, Elam MA, Olorukooba A, et al
    Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics – United States, September 1, 2022-September 30, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:286-290.
    PubMed         Abstract available
    
    
    N Engl J Med
27. GANDHI RT, Hirsch M
    Treating Acute Covid-19 – Final Chapters Still Unwritten.
    N Engl J Med. 2024;390:1234-1236.
    PubMed        
    
28. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
    Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    N Engl J Med. 2024;390:1186-1195.
    PubMed         Abstract available
    
    
    PLoS Comput Biol
29. SHAO Y, Magee AF, Vasylyeva TI, Suchard MA, et al
    Scalable gradients enable Hamiltonian Monte Carlo sampling for phylodynamic inference under episodic birth-death-sampling models.
    PLoS Comput Biol. 2024;20:e1011640.
    PubMed         Abstract available
    
30. ATAMER BALKAN B, Chang Y, Sparnaaij M, Wouda B, et al
    The multi-dimensional challenges of controlling respiratory virus transmission in indoor spaces: Insights from the linkage of a microscopic pedestrian simulation and SARS-CoV-2 transmission model.
    PLoS Comput Biol. 2024;20:e1011956.
    PubMed         Abstract available
    
    
    PLoS Med
31. ELIGULASHVILI A, Gordon M, Lee JS, Lee J, et al
    Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment.
    PLoS Med. 2024;21:e1004263.
    PubMed         Abstract available
    
    
    PLoS One
32. LI Z, Deng X, Mao Y, Duan J, et al
    Study on the temporal and spatial relationship between public health events and the development of air transport scale: A case of the Southwest China.
    PLoS One. 2024;19:e0301461.
    PubMed         Abstract available
    
33. SU X, Wang S
    The impact and management of internet-based public opinion dissemination during emergencies: A case study of Baidu News during the first wave of coronavirus disease 2019 (COVID-19).
    PLoS One. 2024;19:e0299374.
    PubMed         Abstract available
    
34. MARCHANT E, Dowd J, Bray L, Rowlands G, et al
    The well-being and work-related stress of senior school leaders in Wales and Northern Ireland during COVID-19 “educational leadership crisis”: A cross-sectional descriptive study.
    PLoS One. 2024;19:e0291278.
    PubMed         Abstract available
    
35. MO PKH, Xin M, Wang Z, Lau JTF, et al
    Patterns of sex behaviors and factors associated with condomless anal intercourse during the COVID-19 pandemic among men who have sex with men in Hong Kong: A cross-sectional study.
    PLoS One. 2024;19:e0300988.
    PubMed         Abstract available
    
36. BRINKLEY A, Sandercock G, Lowry R, Freeman P, et al
    What determines participation in sport for older adults in England: A multilevel analysis of Active Lives data.
    PLoS One. 2024;19:e0301790.
    PubMed         Abstract available
    
37. FISMAN DN, Amoako A, Simmons A, Tuite AR, et al
    Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    PLoS One. 2024;19:e0297093.
    PubMed         Abstract available
    
38. ZIESEL A, Jabbari H
    Unveiling hidden structural patterns in the SARS-CoV-2 genome: Computational insights and comparative analysis.
    PLoS One. 2024;19:e0298164.
    PubMed         Abstract available
    
39. SHARAN M, Sakthivel M, Rubeshkumar P, Nagarajan R, et al
    Face mask use in the city of Chennai, India: Results from three serial cross-sectional surveys, 2021.
    PLoS One. 2024;19:e0297909.
    PubMed         Abstract available
    
40. SAMSON S, Lord E, Makarenkov V
    Assessing the emergence time of SARS-CoV-2 zoonotic spillover.
    PLoS One. 2024;19:e0301195.
    PubMed         Abstract available
    
41. OZSAHIN DU, Isa NA, Uzun B, Ozsahin I, et al
    Quantifying holistic capacity response and healthcare resilience in tackling COVID-19: Assessment of country capacity by MCDM.
    PLoS One. 2024;19:e0294625.
    PubMed         Abstract available
    
42. STACEVICIENE I, Ivaskeviciene I, Burokiene S, Steponaviciene A, et al
    Epidemiological changes of acute respiratory infections in children: A single-center experience after COVID-19 lockdown.
    PLoS One. 2024;19:e0300877.
    PubMed         Abstract available
    
43. FUJII D, Nakata T, Ojima T
    Heterogeneous risk attitudes and waves of infection.
    PLoS One. 2024;19:e0299813.
    PubMed         Abstract available
    
44. LI B, Xu Y, Wang Y, Zhang B, et al
    DECTNet: Dual Encoder Network combined convolution and Transformer architecture for medical image segmentation.
    PLoS One. 2024;19:e0301019.
    PubMed         Abstract available
    
45. THERESA POOL SN, Shroff EH, Chetty A, Lewis L, et al
    Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    PLoS One. 2024;19:e0299747.
    PubMed         Abstract available
    
46. MWANGI LW, Omuse G, Adam R, Ong’ete G, et al
    Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
    PLoS One. 2024;19:e0299302.
    PubMed         Abstract available
    
47. ANDERSEN KM, Khan FL, Park PW, Wiemken TL, et al
    Using a data-driven approach to define post-COVID conditions in US electronic health record data.
    PLoS One. 2024;19:e0300570.
    PubMed         Abstract available
    
48. MASHA’AL D, Rababa M, Hayajneh A, Shahrour G, et al
    The mediating role of emotional intelligence on nursing students’ coping strategies and anxiety during the COVID-19 pandemic.
    PLoS One. 2024;19:e0300057.
    PubMed         Abstract available
    
49. HERNANDEZ-BELLO J, Lorenzo-Leal AC, Munoz-Valle JF, Morales-Nunez JJ, et al
    Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.
    PLoS One. 2024;19:e0299520.
    PubMed         Abstract available
    
50. WANG Y, Yuan F, Song Y, Rao H, et al
    Prediction of cross-border spread of the COVID-19 pandemic: A predictive model for imported cases outside China.
    PLoS One. 2024;19:e0301420.
    PubMed         Abstract available
    
51. LIEBERTHAL B, Jackson S, de Urioste-Stone S
    Risk perceptions and behaviors concerning rural tourism and economic-political drivers of COVID-19 policy in 2020.
    PLoS One. 2024;19:e0299841.
    PubMed         Abstract available
    
52. CASSUM LA, Lakhani A, Sachwani S, Salim Z, et al
    Beyond the classroom walls: Stakeholder experiences with remote instruction in Post RN baccalaureate nursing program during the COVID-19 pandemic: A qualitative inquiry.
    PLoS One. 2024;19:e0300007.
    PubMed         Abstract available
    
53. ALAMARES-SAPUAY J, Kishko M, Lai C, Parrington M, et al
    Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate DeltaNS2/Delta1313/I1314L increase the stability of infectivity and content of prefusion F protein.
    PLoS One. 2024;19:e0301773.
    PubMed         Abstract available
    
    
    Vaccine
54. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
55. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    PubMed         Abstract available
    
56. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women – El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
57. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    PubMed         Abstract available
    
58. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
59. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
60. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
61. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
62. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
63. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
64. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
65. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
66. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
67. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
68. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
69. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System – United States, September 1, 2022 – March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
70. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
71. LASRADO N, Rossler A, Rowe M, Collier AY, et al
    Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Vaccine. 2024;42:2117-2121.
    PubMed         Abstract available
    
72. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
73. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    “COVID is a huge jigsaw puzzle that I am trying to make sense of myself”: Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
74. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
75. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
76. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
77. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
78. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
79. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination – A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
80. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
81. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
    Virology
82. ZHENG X, Yang R, Zhao Y, Zhang Y, et al
    Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
    Virology. 2024;594:110050.
    PubMed         Abstract available
    
83. NGUYEN CT, Nakayama M, Ishigaki H, Kitagawa Y, et al
    Increased expression of CD38 on endothelial cells in SARS-CoV-2 infection in cynomolgus macaques.
    Virology. 2024;594:110052.
    PubMed         Abstract available